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1 Background  
1.1 Liver transplantation 
Dr. Thomas E. Starzl was the first surgeon to perform a successful deceased donor liver 
transplant procedure in 1963.1 From being considered an experimental procedure in 1983 
by the National Institute of Health, the number of liver transplantations increased steadily 
during the next decades.2 Liver transplantation, the replacement of the native, diseased 
liver by a normal graft, is now accepted as a successful therapeutic option for patients with 
end-stage liver disease. Liver transplantation is indicated for acute liver failure, chronic 
liver failure, cirrhosis, cholestatic and non-cholestatic liver disorders, and metabolic 
disorders causing cirrhosis among others. It is also indicated for hepatocellular carcinoma 
and other selected hepatic malignancies.  
Oslo University Hospital is the only solid organ transplantation centre in Norway. In 
2011 86 liver transplantations (LTx) and three combined liver and kidney transplantations 
were performed at this centre. In Scandinavia, more than 300 annual liver transplantations 
are performed, and more than 5500 in Europe.3 In the 1970s, the overall 1-year survival 
was approximately 30%.4 Advances in surgical techniques, organ preservation, anaesthesia 
and immunosuppressive therapy have improved the long-term survival. The patient 
survival in the Nordic countries was 85% (1 year) and 66% (10 years) and the graft 
survival 83% (1 year) and 61% (10 years) in the years 2000 to 2009.3 
 
1.2 Immunology in allograft transplantation 
Allogeneic transplantation is transplanting an organ between genetic different individuals 
within the same species. The immune response protects the body against foreign attacks 
(i.e. bacteria, virus and cancer). In cases of allograft transplantation, the immune system 
recognizes the graft-antigens as foreign, and triggers a massive immune response with 
attempt to destroy the graft. Without adequate immunosuppressive therapy this response 
will result in either a hyper acute, acute or a chronic rejection.  
Foreign antigens are recognized by the naïve T-lymphocyte through HLA (human 
leukocyte antigen) molecules present on an antigen presenting cell (APC). The HLA is the 
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major histocompatibility complex (MHC) in human, and its function is to present foreign 
peptide antigens (derived from infectious agents or an allograft) at the surface of the APC. 
The antigen presentation by the APC to the T-cell triggers activation and proliferation of 
the T-cell through three specific signals (Figure 1). The first interaction between the T-cell 
and APC is binding of the HLA-antigen complex to the T-cell receptor (TCR:CD3 
complex) (signal 1). Co-stimulating molecules on the APC (CD80 and CD86) binds to 
CD28 on the T-cell and induce a stimulatory signal to the T-cell (signal 2). These signals 
activate three signal transduction pathways: the calcium-calcineurin pathway, the mitogen 
activated protein (MAP) kinase pathway and the nuclear factor-κB (NF-κB) pathway, 
which activates the transcription factors nuclear factor of activated T cells (NFAT), 
activating protein 1 (AP-1) and NF-κB, respectively. This in turn results in mRNA 
synthesis and expression of interleukin-2 (IL-2), CD154 and CD25. CD154 stimulates the 
APC, while IL-2 binds to the IL-2 receptor (CD25) on the T-cell (signal 3). This signal, in 
collaboration with cytokines, activates the mechanistic target of rapamycin (mTOR) 
pathway, leading to an activation of the cell cycle and proliferation of the T-cell. 
 
 
 
Figure 1. APC antigen presentation and T-cell activation (schematic and simplified). Site 
of action of immunosuppressive drugs are indicated. For abbreviations see page 5. 
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1.3 Immunosuppressive therapy in liver transplantation 
Immunosuppression is the prevention or interference with the development of the normal 
immunologic response. After liver– and other solid organ transplantation the recipient 
needs life-long immunosuppressive therapy to avoid an immunological mediated rejection 
of the transplanted graft. The balance between adequate immunosuppression (preventing 
rejection episodes) and avoiding adverse effects is delicate. Under-immunosuppression 
increases the risk of graft rejection episodes, while over-immunosuppression increases the 
risk of opportunistic infections, malignancies and drug-specific adverse effects. The 
immunosuppressive regimens combine drugs with different modes of action. In general, 
the immunosuppressive drugs used after solid organ transplantation can be classified as 
follows: 
- Anti-proliferative agents (azathioprine and mycophenolic acid) 
- Glucocorticoids (prednisolone and methylprednisolone) 
- Calcineurin inhibitors (cyclosporine and tacrolimus) 
- mTOR inhibitors (sirolimus and everolimus) 
- Monoclonal antibodies (basiliximab, daclizumab, alemtuzumab and 
belatacept) 
- Polyclonal antibodies (anti-thymocyte globulin) 
 
In Norway the current immunosuppressive protocol after liver transplantation is a triple 
regimen consisting of corticosteroids, mycophenolic acid and low dose calcineurin 
inhibitor (tacrolimus), while a quadruple regimen is used in renal transplantation (IL-2 
receptor antagonist is added). The rationale behind a multiple regimen is that synergistic 
effects of the drugs are achieved, and the doses of the individual drugs might be reduced, 
resulting in a lower risk of dose-dependent drug specific adverse effects. The risk of 
rejection is highest in the immediate phase after transplantation, therefore a more intensive 
therapy is required during the first days post-transplant with further tapering of the drugs 
according to protocol.5 The immunosuppressive therapy is a life-long treatment, and the 
lowest effective dose of each drug should be used in order to maintain an active immune 
response against infections and to keep side effects at a minimum.  
The glucocorticoid methylprednisolone is administered intravenously pre–, peri– 
and post-operative, and the first day after surgery. Glucocorticoid treatment is switched to 
per oral prednisolone from day two, and then tapered (see Table 1). In the case of an acute 
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rejection episode methylprednisolone (i.v.) is administered. Mycophenolic acid 
(mycophenolate mofetil, MMF) is administered per orally in doses of 1 g twice daily. 
Tacrolimus doses are adjusted according to the whole blood concentration of the drug 
according to the TDM protocol shown in Table 1. In cases of steroid resistant rejection 
episodes anti thymocyte globulin (ATG) is administered intravenously. 
 
 
 
Table 1. Standard triple immunosuppressive protocol after adult (>16 years) liver 
transplantation at Oslo University hospital (per June 2012). Doses given as daily doses. 
Solu-Medrol™ (Pfizer), Prograf™ (Astellas), CellCept™ (Roche) 
 
1.4 Glucocorticoids 
Glucocorticoids are a group of steroid hormones (corticosteroids) synthesized in the 
adrenal cortex. The biosynthesis of glucocorticoids in the adrenal cortex is regulated by the 
adrenocorticotropic hormone (ACTH) from the pituitary, which in turn is regulated by the 
corticotropin releasing hormone (CRH) from the hypothalamus. The synthesis and 
secretion of CRH and ACTH is regulated through negative feedback from the 
glucocorticoids on the hypothalamic-pituitary-adrenal axis (HPA-axis), controlling the 
circulating levels of corticosteroids. The endogenous ligand of the glucocorticoid receptor 
(GR) is cortisol. The metabolic and regulatory effects of glucocorticoids are mediated 
mainly via genomic mechanisms. They influence the balance of carbohydrates (reduced 
uptake and utilization, increased gluconeogenesis), proteins (increased catabolism, reduced 
anabolism) and redistribution of fat. They have anti-inflammatory and immunosuppressive 
Day Glucocorticoids Tacrolimus Mycophenolic acid
post-transplant Methylprednisolone (Solu-Medrol™) (Prograf™) Mycophenolate mofetil (CellCept™)
Prednisolone (generic)
Transplantation Methylprednisolone i.v.:
40 mg at start                   
500 mg before reperfusion
40 mg post-operative
1 80 mg (methylprednisolone i.v.) Starting dose: 0.1 mg/kg/day 1 g x 2
2 80 mg (prednisolone p.o.) further dose adjustment
3 70 mg according to concentration:
4 60 mg
5 50 mg
6 40 mg 5-15 ng/mL
7 30 mg
8-30 20 mg
31-60 15 mg 5-10 ng/mL
61-90 10 mg 5-10 ng/mL
91-180 7.5 mg 5-10 ng/mL
181-360 5 mg 5-8 ng/mL
>360 0 mg (tapering) 3-8 ng/mL 0.5 g x 2
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effects. Glucocorticoids exert their effect on several inflammatory and immunological 
mediators and cells, the vascular system and the HPA-axis. They suppress pro-
inflammatory cytokines (e.g. IL-1β, IFN-α), induce anti-inflammatory cytokines (e.g. 
TGF-β, IL-10) and anti-inflammatory cytokine receptors (e.g. TGF-βR, IL-10R). The 
glucocorticoid also reduce the expression of interleukins (IL-1, IL-2, IL-6, IL-12), 
interferon γ (IFN-γ), tumour necrosis factor α (TNF-α), which results in suppression of 
activated T-cells. The production of eicosanoids and immunoglobulin G is also inhibited. 
Furthermore, glucocorticoids reduce the migration of immune cells to the site of 
inflammation by repression of adhesion molecules. Dendritic cells are switched to IL-10 
production instead of IL-12 by administration of glucocorticoids, which limits the 
differentiation of Th0 to Th1 cells. Glucocorticoid might also have apoptotic effects, which 
is suggested as the mechanism of intravenous methylprednisolone pulse therapy. In 
allograft transplantation the glucocorticoids inhibit the differentiation and antigen 
presentation of macrophages and dendritic cells, and thereby inhibit the initiation of an 
immune response.6 
Glucocorticoids are administered in a wide range of conditions, ranging from those 
that require anti-inflammatory or immunosuppressive treatment (asthma, allergy, 
rheumatoid arthritis, systemic lupus erythematosus, and rejection prophylaxis after organ 
transplantation) and malignancies (leukaemia) to substitution therapy (Addisons disease). 
Prednisolone (Figure 2) is a synthetic glucocorticoid and plays an important role in 
rejection prophylaxis after solid organ transplantation. Prednisolone is well absorbed after 
administration and the oral bioavailability is reported to be 60-100%. Time to reach 
maximum concentration (Tmax) for prednisolone is approximately 1.5 hours.6 Prednisolone 
is bound in plasma to corticosteroid binding globulin (CBG) with high affinity and low 
capacity, and to albumin with low affinity and high capacity. A non-linear reduction in 
prednisolone protein binding from 95% to 60-70% when the serum concentration increases 
from 200 to 800 ng/mL is reported.7 Prednisolone is mainly eliminated by hepatic 
metabolism and renal excretion. It is degraded in the liver and conjugated mainly with 
glucuronic acid and to a lesser degree with sulphates. Cortisol is metabolized to 5α-
tetrahydrocortisol and 5β-tetrahydrocortisol by 5α-reductase and 5β-reductase, 
respectively. The latter also converts cortisone into tetrahydrocortisone. These metabolites 
are excreted into the urine. 8 
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Figure 2. Molecular structure of prednisolone. 
 
The two enzymes 11β-hydroxysteroid dehydrogenase (11β-HSD) 1 and 2 play an 
important role in the pre-receptor regulation of glucocorticoid and mineralocorticoid 
receptor activation. They catalyse the interconversion between the hormonally active 
cortisol (hydroxysteroid) and inactive cortisone (ketosteroid), see Figure 3.9 These two 
enzymes possess different catalytic activities, 11β-HSD1 is mainly a NADP(H) dependent 
reductase (dehydrogenase in vitro) with its catalytic site in the ER-lumen (endoplasmatic 
reticulum). The co-factor NADP(H) is generated in the same cell compartment by the 
hexose 6-phosphate dehydrogenase (H6PDH) and is crucial for the reductase activity of 
11β-HSD1.10 The 11β-HSD2 is a dehydrogenase using NAD as a co-factor with its 
catalytic site facing the cytosol.11,12 The biological activity of glucocorticoids relates to the 
presence of a hydroxyl group at position C11 (e.g. cortisol) of the steroid structure. 
Oxidation of this group to an 11-keto group inactivates the steroid (e.g. cortisone). 
Synthetic glucocorticoids like prednisolone and prednisone are also substrates for 11β-
HSD.13 The 11β-HSD1 enzyme is expressed in liver, lungs, gonads, pituitary, adrenal 
cortex, central nervous system and adipose tissue and supplies the glucocorticoid receptor 
with cortisol.14,15 The function of 11β-HSD2 is to protect the mineralocorticoid receptor 
(MR) against high circulating concentrations of cortisol, and this enzyme is expressed in 
kidneys, colon, salivary glands and placenta.16-20 
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Figure 3. Interconversion between prednisolone (active) and prednisone (inactive) via 
11β-hydroxysteroid dehydrogenase 1 and 2 (11β-HSD1 and 2). 
  
The enzymes 11β-HSD1 and 2 belong to the short-chain dehydrogenase/reductase. They 
share 21% homology, and are encoded by two different genes, HSD11B1 and 
HSD11B2.21—23 Increased and decreased 11β-HSD1 activity has been associated with the 
pathophysiology of common diseases. Cushing’s syndrome (i.e. glucocorticoid excess) can 
cause symptoms of metabolic syndrome (central obesity, glucose intolerance and 
hypertension). Animal studies performed in transgenic rodents, with over-expression of 
11β-HSD1 in liver and adipose tissue, show increased local glucocorticoid concentrations 
and features of metabolic syndrome.24,25 Conversely, inhibition of 11β-HSD1 increases 
insulin sensitivity in humans.26 The 11β-HSD1 is regulated by both hormonal and 
nutritional factors, but there is evidence that genetic factors can contribute to inter-
individual variation in 11β-HSD1 activity. A polymorphism in the intronic enhancer 
(rs12086634) is associated with lower 11β-HSD1 transcriptional activity in vitro.27 
Polymorphisms in the HSD11B1 gene (rs846910 and rs12086634) have been associated 
with type 2 diabetes and hypertension.28-30 Two other HSD11B1 variants (rs846910 and 
rs12086634) are associated with increased levels of 11β-HSD1 mRNA and activity in 
adipose tissue.31 Malavasi et al described that the allelic variant of rs13306421 gave higher 
11β-HSD1 expression and activity in vitro.31,32  
 The 11β-HSD2 enzyme plays an important role in regulating mineralocorticoid 
action, by inactivating cortisol, which has mineralocorticoid action, to cortisone. Thus, 
11β-HSD2 protects the mineralocorticoid receptor (MR) against high circulating 
concentrations of cortisol. Inhibition or absence of this enzyme results in high local 
concentrations of cortisol in mineralocorticoid tissues, which again leads to hypertension 
and hypokalaemia. A previous study found that 16% of patients with essential 
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hypertension had an elevated cortisol/cortisone ratio, suggesting that a defect in 11β-HSD2 
could be involved.33 The single polymorphism G534A in the HSD11B2 was reported by 
Brand et al.34 Further studies of this variant could not report any correlation between the 
G534A polymorphism and hypertension.35-37 Thus the importance of variants in the 
HSD11B2 in essential hypertension is controversial. The rare syndrome of apparent 
mineralocorticoid excess (AME) is caused by inactivating mutations in the HSD11B2 
gene, and more than 30 mutations have been described.38-40  
 The glucocorticoid receptor (GR) is a cytosolic receptor, belonging to the nuclear 
hormone receptor super family and is encoded by the NR3C1 gene. The endogenous ligand 
for GR in human is cortisol, but it is also the target for synthetic glucocorticoids used 
pharmacologically. Its primary mechanism of action is regulation of gene transcription. 
The binding of glucocorticoids to the glucocorticoid receptor induces a series of cellular 
events that results in activation or repression of a network of glucocorticoid responsive 
genes and produces a cellular response.41 After entering the cell, the glucocorticoid (GC) 
binds to the ligand binding domain of GR and forms a GC-GR complex, with a 
conformational change in the GR revealing a DNA binding domain. The GC-GR 
complexes form homodimers and translocates into the nucleus. The complex binds to a 
glucocorticoid responsive element (GRE) in the promoter area of anti-inflammatory genes 
(e.g. lipcortin, inhibitor of κB, IκB), and induces the expression of these, a process called 
transactivation.6 By transrepression the glucocorticoids suppress the expression of pro-
inflammatory genes (e.g. interleukin 1, interleukin 2 and pre-opiomelanocortin) via 
activating protein 1 (AP-1), nuclear factor-κB (NF-κB) and interferon regulatory factor 3 
(IRF3).6,42 The repression of negatively regulated target genes is mediated by negative 
glucocorticoid responsive elements (nGREs).43 In addition to these genomic mechanisms 
of action, the glucocorticoids exert a non-genomic action which is independent of the GR 
interaction. The glucocorticoid may directly interact with the cell membrane, and change 
the properties of the membrane and membrane associated proteins.44 
 Alternative splicing of the NR3C1 gene generates two glucocorticoid isoforms (the 
functional GRα and GRβ with no hormone binding ability), where GRα is the predominant 
one, and is expressed in the cytoplasm of most cells. 45,46 A polymorphism in codon 363 in 
the glucocorticoid receptor gene has been associated with increased cortisol suppression 
and insulin response to exogenous glucocorticoids. 47 Other sequence variants in the 
NR3C1 gene are associated with glucocorticoid resistant syndromes.48,49 
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1.5 Tacrolimus 
In addition to cyclosporine A, tacrolimus (Figure 4) is a widely used calcineurin inhibitor 
(CNI) after solid organ transplantation, and now the preferred CNI in standard 
immunosuppressive protocols. Tacrolimus is a macrolide lactone type calcineurin inhibitor 
first isolated from soil containing the bacteria Streptomyces tsukubaensis. Tacrolimus 
forms a complex by binding to the immunophilin FKBP (FK506 binding protein), which 
inhibits the calcium dependent phosphatase calcineurin.50,51 The tacrolimus-FKBP 
complex inhibits T-lymphocyte signal transduction and proliferation through inhibition of 
the calcineurin mediated de-phosphorylation of the transcription factor NFAT. This 
supresses the transcription of interleukin 2 (IL-2) and inhibits the signal 1 and T-cell 
activation.52 
In organ transplantation, two distinct peroral formulations are available: once daily 
(AdvagrafTM, Astellas) and twice daily (PrografTM, Astellas; plus generic) tacrolimus. The 
twice daily formulation is approved for rejection prophylaxis after kidney, liver and heart 
transplantation while the once daily formulation is approved after kidney and liver 
transplantation. A topical formulation (ProtopicTM, Astellas) is approved for the treatment 
of atopic dermatitis.  
 
 
Figure 4. Molecular structure of tacrolimus. 
 
The rate of absorption and bioavailability of orally administered tacrolimus are highly 
variable, and the bioavailability is poor (mean 25%, range 4-93%).53 Maximum blood 
concentration is normally reached between 0.5 and 1 hour after dose.54 Tacrolimus is 
substrate of both CYP3A4, CYP3A5 and P-glycoprotein, where CYP3A4 and CYP3A5 is 
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responsible for extensive first-pass metabolism in the liver and upper small intestine, while 
efflux pump P-glycoprotein will transport the drug back into the intestinal lumen.55-57 The 
main route of elimination for tacrolimus and its metabolites is the biliary route, where up 
to 95% of the administered dose was excreted into the faeces as metabolites (only trace 
amounts of unchanged drug were detected in urine and faeces).58  
Cytochrome P450 (CYP) is a heme containing family of metabolic enzymes, which 
mainly catalyses oxidation of organic substances (endogenous and exogenous). CYP 
enzymes are the major enzymes involved in drug metabolism and bioactivation, and are 
important in phase I metabolism. The CYP3A subfamily consists of several isoforms: 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43, which have overlapping substrate 
specificities, where CYP3A4 and CYP3A5 are most abundant in adults.59,60 CYP3A is 
involved in the metabolism of more than 50% of the drugs on the market and accounting 
30% of hepatic CYP and more than 70% of small intestinal CYP. In adults CYP3A4 shows 
highly variable expression with 10 to 100-fold differences between individuals in liver and 
up to 30-fold in the intestines.60 The intestinal CYP3A content is reported to be present at 
10-50% of the content in liver.60,61  
In general the CYP3A5 isoform is expressed in lower levels than CYP3A4, but it 
shows genetic variability. In expressers the CYP3A5 might constitute 6-99% of the total 
CYP content in the liver.62 The wild type allele is assigned CYP3A5*1, while the 
CYP3A5*3 allele is the most abundant and functionally important variant.63,64 Only 
individuals carrying the CYP3A5*1 allele produce high levels of full length CYP3A5 
mRNA and thereby express functional CYP3A5 protein.65 The CYP3A5*3 allele, with 
allele frequencies of 85-95% among Caucasians, causes a splicing defect and thereby lack 
of functional CYP3A5 protein.65,66 Individuals carrying the CYP3A5*1 allele have 3-fold 
higher CYP3A protein levels than CYP3A5*3 homozygotes.65 The CYP3A5 expression 
(*1/*1 and *1/*3) has clinical impact, because it leads to more extensive metabolism of 
CYP3A substrates and higher dose requirements. CYP3A4 activity and CYP3A5 genotype 
is reported to explain 56-59% of the variability in tacrolimus dose requirements and 
clearance, while hematocrit explains 4-14% after renal transplantation.67 
Tacrolimus is extensively metabolised by the CYP3A4/5 in liver and intestines, 
forming the main metabolite 13-O-demethyl-tacrolimus.68,69 Renal transplant recipients 
carrying CYP3A5*3/*3 required a lower dosage of tacrolimus than CYP3A*1 carriers.70 
Prednisolone is also a substrate for the CYP3A4/5 enzymes.71 
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P-glycoprotein (P-gp) is a member of the ATP-binding cassette super family and encoded 
by the multi-drug resistance gene (MDR1 or ABCB1). P-gp is an adenosine triphosphate 
(ATP) dependent efflux pump and plays an important role in absorption, distribution and 
response of a drug. This transporter has a wide range of substrates, including 
glucocorticoids and tacrolimus and is often co-located with CYP3A4. P-gp is expressed in 
a variety of tissues including the adrenal glands, blood-brain-barrier, kidneys, liver, lungs, 
stomach, jejunum and colon.60 The mRNA levels increase longitudinally along the 
intestine. The inter-individual variability in P-gp expression was more than eight-fold in 
intestinal biopsies from renal transplant recipients.72 Diarrhoea is also a frequent adverse 
effect of the combination of tacrolimus and mycophenolic acid. An effect on P-gp has been 
reported in cases of diarrhoea, where the P-gp content may be reduced in the intestines. In 
cases of severe and prolonged diarrhoea, reduced P-gp activity in the intestines may be the 
most important explanation for the frequent and significant increase in tacrolimus 
exposure.73 
 
1.6 Mycophenolic acid 
Mycophenolate mofetil (MMF, CellCeptTM, Roche and generic) is the 2-morpholinoethyl 
ester of mycophenolic acid (MPA). MPA (Figure 5) is also available as the enteric coated 
sodium salt (EC-MPS, MyforticTM, Novartis). Mycophenolic acid is the active moiety of 
both MMF and EC-MPS. As rejection prophylaxis, it is approved after kidney, liver and 
heart transplantation. 
 
 
 
Figure 5. Molecular structure of mycophenolic acid. 
 
After oral administration, mycophenolate mofetil (MMF) is rapidly hydrolyzed by 
esterases to MPA, and absorbed in the upper gastrointestinal tractus. The oral 
bioavailability was reported to be 94% in healthy volunteers and 81% in renal transplant 
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recipients.74,75 MPA is highly bound to plasma albumin, approximately 97-99%.76-78 
Maximum plasma concentration after MMF administration usually occurs between 1 and 2 
hours, while EC-MPS has lag-time of 0.25 to 1.25 hours.79,80 
MPA is conjugated to glucuronic acid by UDP-glucuronosyltransferases (UGTs) in 
the liver, intestine and kidneys, and more than 90% of the administered dose is excreted in 
the urine as the inactive metabolite 7-O-MPA-glucuronide (MPAG).80-82 MPAG is secreted 
into the bile by the multidrug resistance-associated protein 2 (MRP-2) in the hepatocytes.83 
In the intestines the MPAG is hydrolyzed back to MPA and reabsorbed. This enterohepatic 
circulation contributes 37% (range 10-61%) of the total MPA exposure.74 MPAG is mainly 
formed by UGT1A9 in liver, kidney and GI, but other UGTs are also involved.81,82 Uridine 
5'-diphospho-glucuronosyltransferase (UGT) is a family of phase II conjugating, 
metabolizing enzymes, which are responsible for glucuronidation of endogenous and 
exogenous compounds, normally making them more water-soluble and more easily 
eliminated. There are two main families of UGT-enzymes, UGT1 and UGT2, where 
UGT1A, UGT2A and UGT2B are subfamilies. The pharmacologically active acyl-
glucuronide (AcMPAG) is formed by UGT2B7, and is suggested as a contributor to the 
gastrointestinal toxicity related to MPA.82,84,85 Additionally, another minor metabolite has 
been identified, the phenolic 7-O-glucoside (MPAGl), which is pharmacologically 
inactive.86 See figure 6 for a summary of the metabolic pathway of MPA.  
 
Figure 6. Pharmacokinetics of mycophenolic acid. 
Free mycophenolic acid (fMPA), uridine diphosphate-glucuronosyltransferase (UGT), 7-
O-glucuronide (MPAG), acyl glucuronide (AcMPAG), 7-O-glucoside (MPAGl) 
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UGT1A9 shows a large degree of sequence variability, which alters the expression and 
enzyme activity.87 An increased glucuronidation capacity is observed in individuals 
carrying the c.-2152C>T (rs17868320) and c.-275T>A (rs6714486) variants, which gives 
lower MPA exposure and an increased risk of graft rejection.87-93 The sequence variants 
UGT2B7*2 (rs7439366), UGT1A9 c.-440>T (rs2741045) and c.-331T>C (res2741046) are 
associated with reduced glucuronidation activity and increased concentrations of MPA, 
while UGT2B7*2 and UGT1A8*2 are associated with increased and reduced MPA related 
side effects, respectively.94-98  
MPA is a selective and reversible inhibitor of inosine monophosphate 
dehydrogenase (IMPDH). IMPDH catalyses the oxidation of inosine-5’-monophosphate 
(IMP) to zanthosine-5’-monophosphate (XMP), which is the rate-limiting step in the de 
novo synthesis of guanine and deoxyguanine (figure 7). While other cells more efficiently 
recirculate purines from a salvage pathway, T- and B-lymphocytes are relative dependent 
on the de novo synthesis for proliferation. This gives mycophenolic acid a potent cytostatic 
effect on lymphocytes.99  
 
Figure 7. The de novo synthesis of guanine and deoxyguanine nucleotides. Phosphoribosyl 
pyrophosphate (PRPP), inosine monophosphate (IMP), mycophenolic acid (MPA), IMP 
dehydrogenase (IMPDH), nicotinamide adenine dinucleotide (NADH), reduced form of 
NADH (NAD+) dixanthosine monophosphate (XMP), guanosine mono-/di-/triphosphate 
(GMP, GDP, GTP), deoxyguanosine di-/triphosphate (dGDP, dGTP), ribonucleic acid 
(RNA) and deoxyribonucleic acid (DNA). 
 
    
Two distinct isoforms of IMPDH have been reported (IMPDH 1 and 2), where MPA is a 
fivefold more potent inhibitor of the type 2 isoform (IMPDH2), which predominates in 
activated lymphocytes, but both IMPDH 1 and 2 mRNA are induced after lymphocyte 
activation.100-102 IMPDH 1 and 2 are encoded by the IMPDH1 and IMPDH2 genes, 
respectively.102 Intra- and inter-individual variability in the IMPDH activity (basal, without 
inhibitor) and the degree of enzyme inhibition under MPA therapy has been 
described.103,104 Furthermore, activation of lymphocytes increases the IMPDH activity and 
changes the immune status, resulting in variable IMPDH activity and MPA response.103-105 
Sequence variants in the IMPDH 1 and IMPDH 2 genes can add further variability 
between individuals, resulting in an altered pharmacodynamic response. Two IMPDH1 
single nucleotide polymorphisms (SNPs: rs227893 and rs2278294) were reported by Wang 
et al. that were significantly associated with the incidence of biopsy proven acute rejection 
(BPAR) in the first year after renal transplant recipients receiving MPA therapy.105 The 
presence of a IMPDH2 3757 T>C variant allele (rs11706052) is associated with an 
increased IMPDH activity in MMF-treated renal transplant patients, and triples the odds 
for BPAR within 12 months after renal transplantation.106,107 Large inter-individual 
variation of IMPDH enzyme activity pre-transplant has been observed.108 The IMPDH2 
3757 T>C variant has been reported to explain 8% of the inter-patient variability in 
IMPDH activity.106  
 
1.7 Principles of therapeutic drug monitoring 
The main purpose of therapeutic drug monitoring (TDM) is to individually adjust the dose 
of a drug to improve the outcome of the therapy. Criteria for drugs considered for 
therapeutic drug monitoring are as follows: 
- Narrow therapeutic window (small changes in dose and exposure can result in 
toxicity or loss of efficacy) 
- Failure of drug treatment has serious consequences for the patient 
- Relationship between dose and blood concentration is poorly predictable 
- The clinical effect is difficult to quantify 
- Considerable pharmacokinetic and pharmacodynamic variability between 
individuals 
- The observed variable is associated with pharmacological effect and clinical 
outcome 
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- Therapeutic range of the measured variable must be established 
- Assays for monitoring must be available 
- Cost and benefit must be reasonable 
 
There are several approaches for monitoring of drug therapy. It can be based on 
individualization before the therapy is started (pharmacogenetics, demographic and clinical 
information) or after (the pharmacokinetic or pharmacodynamic approach). TDM is a 
valuable tool for establishing the optimal drug concentration short-term after therapy 
initiation and in cases of drug interactions.  
A simple definition of pharmacokinetics is what the body does to the drug. This 
includes the time course of absorption, distribution, metabolism and elimination of the 
administered drug. Several factors are known to affect the pharmacokinetics of a drug: 
absorption, tissue and body fluid mass and volume, genetic factors, elimination (e.g. renal 
function) drug metabolism and drug interactions. Pharmacokinetic monitoring is the most 
widespread form of TDM and is based on measurements of blood concentrations of the 
drug. These measurements are based on either single point concentrations (C0 or C2) or 
drug exposure (area under the time-concentration curve, AUC). The trough concentration 
(C0) is the drug concentration at the end of a dosing interval just before the next dose, 
while the C2 is the drug concentration two hours after administered dose. A full AUC is 
considered as the best marker for drug exposure. Compared to a single point measurement 
a full AUC requires several sampling time points to cover the dosing interval (normally 12 
hours), which is both time- and labour-consuming. The use of single point measurements 
assumes that there is a correlation between e.g. C0 and the AUC, and that C0 can predict the 
exposure. Abbreviated AUC (e.g. AUC0-2) and limiting sampling strategies (normally 3 
time points and a mathematical algorithm) have been proposed as an alternative to a full 
AUC, but they are still time-consuming. C0 is therefore the most common variable to 
measure in terms of pharmacokinetic monitoring. For cyclosporine A (CsA) the C2 
concentration correlates better with drug exposure, and is an established way for 
monitoring monitor CsA. A newer strategy in therapeutic drug monitoring is the use of 
population pharmacokinetics combined with Bayesian estimators. 
Pharmacodynamics is defined as what the drug does to the body, and refers to the 
relationship between drug concentration at the site of action and the efficacy. 
Pharmacodynamic monitoring uses biological surrogate or end-point markers for effect 
(e.g. target enzyme activity), and reflect the biological response of the drug more closely to 
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the site of action than the pharmacokinetic approach. Factors that may affect the 
pharmacodynamics of a drug are drug receptor status, genetic factors, pharmacodynamic 
drug interactions and tolerance.  
 
1.8 Therapeutic drug monitoring of immunosuppressive 
drugs 
The goal of the monitoring of immunosuppressive therapy after solid organ transplantation 
is a treatment individualized to each patient. This therapy is a delicate balance in order to 
avoid over- or under-immunosuppression. Overexposure of immunosuppressive drugs 
increases the risk of drug related adverse effects, opportunistic infections or malignancies, 
while underexposure might cause acute or chronic rejection and graft loss. Both cases 
might result in impaired quality of life and high costs. The optimal dosing of 
immunosuppressive drugs can be achieved by therapeutic drug monitoring. The risk of 
rejection episodes after transplantation is highest short-term after transplantation.5 
Reaching the recommended target concentrations of the immunosuppressive drugs as 
shortly as possible after transplantation is crucial for optimal, clinical outcome. 
The maintenance immunosuppressive therapy after liver transplantation consists of 
prednisolone, tacrolimus and mycophenolic acid. These drugs are associated with a broad 
range of adverse effects. Glucocorticoids (e.g. prednisolone) have a large number of side 
effects: risk of infection, diabetes mellitus, hypertension, dyslipidaemia, weight gain, 
osteoporosis, Cushingoid symptoms, glaucoma, suppression of the adrenal cortex, growth 
retardation in children, skin atrophy and neurological side effects like insomnia, irritability, 
psychosis and mood changes.6 The most abundant side effects of tacrolimus are 
nephrotoxicity, diabetes mellitus, tremor, headache, alopecia, diarrhoea, nausea and 
vomiting.62 Drug-specific adverse effects related to mycophenolic acid include leukopenia, 
diarrhoea, nausea, vomiting and an increased risk of CMV-infection (cytomegalovirus).77 
Today, the rejection rate in liver transplant recipients is relatively low (see section 
1.1). One of the main purposes of therapeutic drug monitoring nowadays is to optimize the 
therapy to improve quality of life, reduce the drug related toxicity and to reach the lowest 
dose possible while maintaining the optimal protection against graft rejection. 
In the standard immunosuppressive regimen after liver transplantation, only tacrolimus is 
subject for routinely therapeutic drug monitoring. Tacrolimus pharmacokinetics is highly 
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variable between individuals. The established TDM of tacrolimus is based on single point 
pharmacokinetic measurements, by measuring the pre-dose concentration (i.e. 
concentration at the end of the dosing interval, right before the next dose = C0) in whole 
blood. The recommended target trough concentration, according to the protocol at our 
transplantation centre, is 5-15 ng/mL (1-30 days post-transplant), 5-10 ng/mL (31-180 days 
post-transplant), 5-8 ng/mL (181-360 days post-transplant) and 3-8 ng/mL a year post-
transplant. In patients with elevated creatinine, the clinicians aim at the lower end of the 
recommended concentration range (5-15 ng/mL) in the early post-operative period, in 
order to manage the renal function of the patient, due to tacrolimus nephrotoxicity. 
Several of the marketed immunosuppressive drugs have a narrow therapeutic 
window, which increases the risk of complications in cases of clinical relevant drug 
interactions. When a drug interaction is likely to occur, monitoring might be of value to 
evaluate whether individual dose adjustments are necessary. As described in section 1.5 
tacrolimus is mainly metabolized by the CYP3A enzyme, hence inhibition or induction of 
CYP3A4-mediated metabolism is a clinically important drug interaction for tacrolimus. 
Some relevant interactions of clinical importance are caused by grapefruit juice and co-
administration of antifungal drugs. Grapefruit juice contains an array of furanocoumarins 
responsible for the inhibition of CYP3A,109 which increases the oral bioavailability of 
tacrolimus. This drug interaction is sometimes used intentional to improve the uptake of 
orally administered tacrolimus. Due to the immunosuppressive state of the transplanted 
patients, antifungal drugs are frequently administered. The antifungal drugs fluconazole, 
itraconazole and ketoconazole increase the exposure of tacrolimus through inhibition of 
CYP3A with variable potency.110 Co-administration of ketokonazole almost doubles the 
bioavailability of tacrolimus.111 In cases of this drug interaction, close monitoring is 
essential for dose adjustment after initiation and discontinuation of these drugs. The human 
pregnane X receptor (PXR), encoded by NR1I2, regulates the expression of the CYP3A and 
MDR1 genes.112,113 Glucocorticoids induce CYP3A expression through PXR in 
hepatocytes and enterocytes.112 Induction of CYP3A expression increases the metabolism 
of CYP3A substrates, which results in increased dose requirements of these drugs (e.g. 
tacrolimus). The clinically relevant drug interactions between tacrolimus and other 
frequently administered drugs after transplantation and the potential complications 
highlight the importance of controlling the tacrolimus levels and dosing.  
 Several studies have demonstrated that patients carrying the CYP3A5*1 allele 
require higher doses of tacrolimus than the CYP3A5*3 carriers to reach the same blood 
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concentrations.114-116 Renal transplant recipients with at least one CYP3A5*1 allele 
achieved only half the dose-normalized tacrolimus blood concentrations compared to 
CYP3A5*3/*3 homozygotes, with a significant delay in reaching target blood 
concentrations in the CYP3A5*1 carriers.115 CYP3A5 genotyping in renal transplant 
recipients is predictive of the tacrolimus dose, and may help determine the initial daily 
dose of tacrolimus needed by the individual patient for adequate immunosuppression.117 
These findings might indicate that an individualized immunosuppressive therapy based on 
pharmacogenetics is promising after solid organ transplantation.  
Considerable inter-individual variability in the pharmacokinetic parameters of 
MMF has been reported.118 Considering the correlation between MPA plasma 
concentration and risk of acute rejection and the variability in MPA pharmacokinetics, 
individualizing the dose regimen of MMF may improve clinical outcome. Higher MPA 
plasma concentrations are correlated with a reduced risk of acute rejection in renal 
transplant recipients, hence controlling this variability is of clinical importance.119 In the 
same study, the pharmacokinetic-pharmacodynamic relationship was investigated showing 
a significant relationship between MPA AUC0-12h and the risk of rejection and that pre-
dose concentrations of MPA (C0) has less predictive value of acute rejection than AUC0-
12h. A therapeutic range of MPA AUC0-12h between 30 and 60 mg*h/L has been 
suggested.120 The value of therapeutic drug monitoring of MPA has been widely discussed, 
but single point C0 measurements are performed by several centres, despite poorer 
correlation with clinical outcome than AUC. As therapeutic drug monitoring by full AUC 
sampling is both time and labour consuming in daily routine, another approach has arisen. 
Two large multicentre trials (APOMYGRE and FDCC) investigated a potential benefit in 
clinical outcome in renal transplant recipients, by individualizing MMF dosing by using 
three-point limited sampling strategies.121,122 The APOMYGRE-trial demonstrated, by 
using a Bayesian estimator, that there was a significantly lower incidence of biopsy proven 
acute rejections in the concentration-controlled group than the fixed-dose group. The 
FDCC-trial found no difference in the incidence of treatment failure between the 
concentration-controlled group and the fixed-dose group. The lack of difference in MPA 
exposure between the concentration-controlled group and the fixed-dose group may partly 
be explained by failure to apply MMF dose changes based on target MPA exposure. 
Although conflicting results in these studies, the results in the APOMYGRE-trial showed 
that clinical outcome after renal transplantation might be improved by individualizing 
MMF dosing.  
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As described in section 1.8, sequence variants in the UGT1A9 gene might describe 
some of the pharmacokinetic variability of MPA. Although further documentation is 
needed, determination of UGT1A9 genotype might prove valuable as a supplement in 
further individualization of MPA treatment. Further discussion of this topic is presented in 
section 4.3. 
As MPA inhibits the IMPDH in lymphocytes, measuring IMPDH activity in these 
cells might serve as a surrogate marker for MPA-induced immunosuppression. The 
pharmacokinetic approach to therapeutic drug monitoring of MPA uses the plasma 
concentration as the marker for the clinical effect. Pharmacodynamic monitoring measures 
the pharmacological effect more closely at the drug target, and will predict the efficacy and 
toxicity of MPA more directly. Pharmacodynamic monitoring of MPA is further discussed 
in section 4.8. 
Glucocorticoid therapy is a cornerstone in the immunosuppressive regimens after 
organ transplantation. As mentioned in section 1.8 these drugs have a broad range of 
serious side effects. Despite the serious side effect profile of glucocorticoids and the long-
term therapy, no concentration monitoring or individualized dosing is performed after 
adult solid organ transplantation. Several studies aiming to avoid or withdraw steroids in 
the immunosuppressive regiment have been published with positive results, but the results 
are conflicting.123-126 Knight et al. reported that steroid avoidance or withdrawal decreases 
the risks of various side effects, but increases the risk of acute rejection.127,128 In the 
APOMYGRE-study mentioned above, they demonstrated a significant reduction in 
treatment failure in the concentration-controlled group (of MPA) combined with steroid 
withdrawal.121 
Although the single point pharmacokinetic monitoring as performed today is a 
valuable tool in therapeutic drug monitoring, it is only a surrogate marker for the drug 
exposure and predicted efficacy of the drug. The primary end-point of immunosuppressive 
therapy is the degree of immunosuppression and avoidance of graft rejection. 
Pharmacodynamic monitoring is measuring the biological response to a drug, which in 
addition to pharmacokinetic monitoring offers an improved method for optimization of 
drug dosing. As a supplement to established TDM, monitoring of immune status can give 
an indication whether the patient has a low, moderate or strong immune response, and 
identify patients at risk of acute rejection, infection or cancer. Rejection episodes, 
infections and cancer development are important sources of morbidity and mortality in 
immunosuppressed patients. An FDA approved commercial analysis kit has been marketed 
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(ImmuKnow®, CylexTM Inc., Columbia, MD), which is an immune cell function assay and 
quantifies intracellular ATP (adenosine triphophate) in stimulated CD4 positive 
lymphocytes. Although the predictive value of this kit has been debated, a meta-analysis 
performed by Rodrigo et al. concludes that the ImmuKnow test is a valuable tool to predict 
the risk of further infections in adult liver transplant patients, but the identification of the 
risk for rejection is inconclusive.129  
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2 Objectives of the thesis 
2.1 Overall objective 
The liver plays a crucial role in the pharmacokinetics of immunosuppressive drugs. The 
overall objective of this thesis was to investigate the pharmacokinetics, pharmacodynamics 
and pharmacogenetics of the immunosuppressive drugs used after liver transplantation; 
glucocorticoids, mycophenolic acid and tacrolimus. Furthermore, the aim was to describe 
the intra– and inter–individual variability of these drugs in liver transplant recipients and to 
study which underlying factors contribute to the large variability in the clinical effect of 
these drugs.  
 
2.2 Objective paper I 
This paper aimed to develop a reliable LC-MS/MS assay for quantifying six relevant 
glucocorticoids (prednisolone, prednisone, cortisol, cortisone, methylprednisolone and 
dexamethasone) used after solid organ transplantation. An in-depth validation study should 
be performed according to the U.S. Food and Drug Administration guidelines.130 
Furthermore, the matrix effects should be assessed and the clinical application 
demonstrated. 
 
2.3 Objective paper II 
The objective of this second paper was to investigate the pharmacokinetics of prednisolone 
and prednisone in the first weeks following liver transplantation. The impact of the 
metabolizing enzymes 11β-hydroxysteroid dehydrogenase 1 and 2 on the pharmacokinetics 
of prednisolone and prednisone should be studied. Furthermore, the study aimed to 
investigate the ratio between prednisolone and prednisone as a potential marker in 
therapeutic drug monitoring. Additionally, the pharmacokinetics of methylprednisolone 
and endogenous cortisol and cortisone should be described. 
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2.4 Objective paper III 
The aim of this study was to examine the pharmacokinetics, –dynamics and –genetics of 
mycophenolic acid early after liver transplantation, with respect to IMPDH activity and 
UGT1A9, IMPDH1 and IMPDH2 sequence variants. Furthermore, the study aimed to 
describe the pharmacokinetics and pharmacogenetics of the calcineurin inhibitor 
tacrolimus in the same patient population. By genotyping both donors and recipients for 
sequence variants in the CYP3A5 gene, the association between CYP3A5 genotype and the 
tacrolimus pharmacokinetics should be investigated.  
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3 Methods 
3.1 Study design and patient recruitment 
The study population reported in paper II and III were recruited at Oslo University 
Hospital in the period between February 2008 and July 2009. Sixteen liver transplant 
recipients were included. The inclusion criteria were liver transplant recipients at ages 
above 18 years, immunosuppressive therapy according to the standard protocol after liver 
transplantation, consisting of a triple regimen with prednisolone, mycophenolic acid and 
tacrolimus and no former use of these immunosuppressants. The study was performed in 
accordance with the Declaration of Helsinki and approved by the Regional Committee for 
Medical Research Ethics. Informed written consent from the study participants was 
obtained.  
The study period included the first three weeks following liver transplantation. Full 
12-hour pharmacokinetic profiles were obtained on up to four follow-up days for each 
patient. The first follow-up day was between day one and five post-transplant, the second 
between day six and ten, the third between day 11 and 17, while the fourth dosing interval 
was after day 17. The four follow-up days are reported as period I, II, III and IV, 
respectively. All four follow-up days were completed in 8 and 9 of the 16 recipients for 
tacrolimus and mycophenolic acid, respectively. Two of the recipients had complications 
with the central venous catheter, which resulted in only two and three intervals for these 
patients. Because of medical conditions at the inclusion time one patient missed the first 
period. Four of the patients were recovering fast and were discharged from the hospital 
prior to period IV. One of the patients started anti-thymocyte globulin (ATG) treatment 
during one of the follow-up days, and these samples were unsuitable for the IMPDH-assay, 
due to eradication of T-lymphocytes. For the tacrolimus study, one of the patients was 
excluded from the pharmacokinetic analysis due to administration of once-daily tacrolimus 
(Advagraf), which was not in accordance with the study protocol. Lastly, one of the 
intervals was excluded due to assay failure (IMPDH) and another one because of 
inappropriate timing of tacrolimus and MMF dose.  
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3.2 Sampling and pre-analytical preparation 
Samples were collected peripherally pre-transplant (pre-Tx) and from a central venous 
catheter at four follow-up days in four distinct periods during the three weeks after surgery. 
Biological samples consisted of whole blood for genotype analyses, isolated CD4+ 
lymphocytes for gene expression analyses and IMPDH activity measurement, whole blood 
for tacrolimus concentration assessment and plasma for quantification of mycophenolic 
acid and glucocorticoid concentrations. The venous blood samples were drawn into tubes 
containing EDTA (ethylene diamine tetraacetic acid). Each follow-up day was a twelve 
hour dosing interval with thirteen samples (pre-dose, 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3, 4, 5, 6, 8, 
10 and 12 hours post-dose). CD4+ lymphocytes for IMPDH activity, plasma and whole 
blood for drug concentration measurements were collected at all time points. Pre-
transplant, samples were drawn for genotyping and basal IMPDH activity. In addition, 
whole blood from the respective liver donors was collected for genotype determination.  
At the sampling days, a large effort had to be made isolating and providing the right 
biological material for the separate analyses. Whole blood collected pre-Tx for genotyping 
was frozen at -70 °C directly after sampling. After freezing an aliquot of whole blood for 
tacrolimus analysis at -20 °C, the remaining sample was centrifuged at 1500 g in 12 
minutes to separate the plasma in aliquots for glucocorticoid and MPA analyses. The 
plasma samples were frozen at -20 °C until analysis. 
For the IMPDH activity assay, CD4+ lymphocytes were isolated from whole blood 
using paramagnetic monodisperse beads coated with anti-CD4 monoclonal antibodies 
(Dynabeads® M-450 CD4, Life Technologies). EDTA (ethylenediaminetetraacetic acid) 
whole blood was incubated with beads, plasma removed and the captured cells were 
washed with phosphate buffered saline (PBS) sequentially. The plasma from the samples 
was subjected to 0.1 μm filtration. To restore the intracellular MPA concentration, the 
isolated lymphocytes were re-incubated in the micro-filtrated original plasma or drug-free 
plasma, depending on whether the inhibited or the basal IMPDH activity was to be 
measured. After lysis of the cell membranes the cell nuclei from the isolated lymphocytes 
were counted using a Coulter Counter® (Beckman Coulter, Inc.), which was set at a 
diameter range of 3 to 10 μm. The remaining suspension was frozen at -20 °C until 
analysis. 
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3.3 Pharmacokinetic analyses 
The pharmacokinetic variables and parameters for glucocorticoids (paper II), tacrolimus 
(paper III), mycophenolic acid (paper III) were derived from plasma (MPA and 
glucocorticoids) and whole blood (tacrolimus) as follows. Maximum concentration (Cmax), 
pre-dose concentration (C0) and time to reach Cmax (Tmax) were read directly from the 
concentration versus time curves. The elimination rate constant (ke) was estimated by log–
linear regression of the terminal part of the concentration–time profile. Elimination half–
life is calculated as ln2/ke. By using the linear trapezoidal rule the area under the 
concentration–time curve (AUC0-12h) was calculated. AUC12-∞ was extrapolated by C12 
divided by ke. Total AUC0-∞ is the sum of AUC0-12h and AUC12–∞, minus the contribution 
from previous dose of tacrolimus or mycophenolic acid (C0/ke). The apparent total 
clearance from plasma after an oral dose (Cl/F) was determined from the dose divided by 
the AUC0-∞. Apparent volume of distribution (VD/F) was calculated as (Cl/F)/ke. The data 
are based on single-compartmental pharmacokinetics. The pharmacokinetic data of 
tacrolimus, glucocorticoids and MPA were normalized to dose per bodyweight (dose/BW).  
 
3.4 Statistical analyses 
The statistical analysis, calculation and figure preparation were carried out using SPSS 
18.0 (SPSS Inc., Chicago, IL) and Microsoft Excel (Microsoft Corp., WA). All continuous 
variables were reported as median and range, unless otherwise stated. To compare changes 
in pharmacokinetic parameters and variables between the four periods Related-Samples 
Wilcoxon Signed Rank Test was used. Statistical bivariate correlation was investigated by 
Spearman’s rank correlation coefficient. In paper III the Kruskal Wallis Test was used in 
order to test whether there were differences in MPA pharmacokinetics between the three 
groups of UGT1A9 genotypes. P-values less than 0.05 were considered statistical 
significant.  
 
3.5 Paper I 
To investigate glucocorticoid pharmacokinetics in clinical samples, an LC-MS/MS 
(tandem mass spectrometry coupled to high performance liquid chromatography) assay for 
quantifying prednisolone, prednisone, cortisol, cortisone, methylprednisolone and 
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dexamethasone was developed. The LC-MS/MS method was validated according to the 
bioanalytical guidelines published by U.S. Food and Drug Administration, validating 
stability, precision, accuracy, sensitivity, selectivity and linearity. 130 Additionally, matrix 
effects were validated both qualitatively and quantitatively. Quantification of plasma 
concentrations in plasma were performed by reversed phase chromatography, coupled to 
positive electrospray ionization with multiple reaction monitoring in the mass 
spectrometer. The chromatographic column in use was a Luna C18, 3 μm, 150 mm x 4.60 
mm (Phenomenex, Torrance, CA), with a gradient elution with methanol and 2 mmol/L 
ammonium acetate with 0.1% formic acid (v/v). Sample preparation and pre-treatment 
consisted of protein precipitation with acetonitrile with isotope labelled internal standards, 
followed by liquid/liquid extraction with dichloromethane, evaporation under nitrogen (40 
°C, 15 min) and re-constitution in methanol. The assay was developed using a HPLC 
(Alliance HT 2795, Waters, Manchester, UK) coupled to a tandem mass spectrometer of 
the triple quadropole type (Micromass Quattro Micro, Waters, Manchester, UK) using 
positive electrospray ionization (ESI+) with multiple reaction monitoring (MRM). Data 
were processed using the MassLynxTM and QuanLynxTM software supplied by Waters. 
Linear least-squares regression of peak area was used for calibration of each analyte, with 
1/(analyte concentration)2 weighting of the calibration curve. 
 
3.6 Paper II 
Determination of plasma concentrations of prednisolone, prednisone, cortisol, cortisone 
and methylprednisolone in the liver transplant population were determined by the validated 
LC-MS/MS method presented in paper I. The pharmacokinetic analyses were performed 
according to section 4.3. In addition, the ratio between active and inactive glucocorticoids 
(i.e. prednisolone and prednisone) was calculated as the AUC0-∞, C0 or Cmax of 
prednisolone divided by that of prednisone. 
 
3.7 Paper III 
Quantification of mycophenolic acid concentrations in plasma was performed by a LC-UV 
(HP series 1100 and HP Chemstation, Agilent Technologies, CA) assay published earlier, 
and used in the daily routine in our laboratory.131 This is a reversed phase LC-method, 
using a Zorbax SB-C18 column, 3.5 μm, 74 x 4.6 mm with a Zorbax Eclipse XDB-SB-C8 
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guard cartridge, 5 μm, 12.5 x 2.1 mm (Agilent Technologies, CA). Isocratic elution with a 
mobile phase containing 30% acetonitrile and 40 mM phosphoric acid (pH 2.1) was 
performed. Protein precipitation with acetonitrile is used as sample purification. For 
detection the UV-absorption is measured. 
Determination of inosine monophosphate dehydrogenase (IMPDH) activity was 
performed in isolated CD4+ cells and quantified by HPLC with UV-detection (HP Series 
1100, Agilent Technologies, Palo Alto, CA), expressed as the XMP (xantosine 
monophosphate) production rate (pmol/106/cells/min).131 The lymphocytes were isolated 
from whole blood by utilization the use of of paramagnetic beads coated with anti-CD4 
antibodies. To restore the intracellular concentration of MPA after the sequential washing 
steps, the cells were incubated in micro filtrated plasma from the original sample. 
Additionally, at four time points the MPA was washed out and restored in drug free 
plasma, to measure the basal IMPDH activity. Inosine 5’-monophosphate (IMP) is the 
substrate for IMPDH. Together with nicotinamide adenine dinucleotide (NAD), which is 
the co-factor for IMPDH, IMP was added to the lysate of the CD4+ cells, and IMPDH 
activity was quantified as the xanthosine 5’monophosphate (XMP) production rate 
(pmol/106cells/min). The concentration of XMP was determined by HPLC after hydrolytic 
cleavage to xanthine, using a Chromolith Performance column, 100 x 4.6 mm (Merck, 
KgaA, Darmstadt, Germany) coupled in series with a Nucleosil C18 column, 5 μm, 150 x 
4.6 mm (Supelco Inc., Bellefonte, PA). The mobile phase contained methanol 4% in o-
phosphoric acid with pH 1.8, where the analytes were eluted using isocratic flow. 
Concentration assessment of the calcineurin inhibitor tacrolimus was carried out by 
an LC-MS/MS assay developed, validated and published from our laboratory.132 Instead of 
using the reported standards and quality controls in this method, a commercial kit was used 
(Mass Trak Immunosuppressants Kit, Waters, Manchester, UK). Whole blood samples 
were cleaned up by protein precipitation with 0.1 mol/L zinc sulphate and acetonitrile 
containing internal standard. The prepared samples were analysed with reversed phase 
chromatography on a Luna C18(2) cartridge 3μm, 20 x 2.0 mm with a guard cartridge C8 
4.0 x 2.0 mm (Phenomenex, Torrance, CA), using mobile phases containing 2.0 mmol/L 
ammonium acetate and 0.1% formic acid (v/v) in methanol and water, respectively. The 
mass spectrometer was set in the positive electrospray mode with multiple reaction 
monitoring.  
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Samples for clinical biochemistry variables were collected and analysed as a part of the 
standard post-transplant follow-up on a daily basis in the study period. The biochemical 
parameters alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), total 
bilirubin and albumin were analysed in heparin plasma on the Modular Analytics analyser 
(F. Hoffmann- La Roche Ltd, Basel, Switzerland).  
Genotyping of CYP3A5, UGT1A9, IMPDH1 and IMPDH2 was performed by PCR 
and melt curve analysis with hybridization probes on the LightCycler® 480 instrument 
(Roche Applied Science, Penzberg, Germany) after DNA extraction from EDTA anti-
coagulated blood using the MagNA Pure instrument (Roche Applied Science, Penzberg, 
Germany). The following sequence variants were determined: 
CYP3A5 (rs 776746; g.12083A>G, A=CYP3A5*1 and G=CYP3A5*3) 
UGT1A9 (rs17868320, c.-2152C>T) 
UGT1A9 (rs2741046, c-440C>T) 
UGT1A9 (rs2741045, c-331T>C) 
UGT1A9 (rs6714486, c.-275T>A) 
IMPDH1 (rs2278293, c.579+119G>A) 
IMPDH1 (rs2278294, c.580-106G>A) 
IMPDH2 (rs11706052, c.819+10T>C) 
In order to investigate the pharmacodynamics of mycophenolic acid, the IMPDH activity 
was examined as follows. The pre-dose, minimum and maximum enzyme activities were 
read directly from the IMPDH activity versus time curve, and called A0, Amin and Amax, 
respectively. The time points for Amin and Amax were assigned Tmin and Tmax. The 
maximum IMPDH inhibition was calculated by the formula (1-Amin/A0) x 100%. 
    	
4 Results and discussion 
4.1 Paper I 
This paper presents a quantitative assay for determination of prednisolone, prednisone, 
cortisol, cortisone, methylprednisolone and dexamethasone in plasma samples. The 
validation results are in accordance with the bioanalytical guidelines published by U.S. 
Food and Drug Administration. 130 According to these guidelines the assay intra-day and 
inter-day precision should have coefficients of variation lower than 15% (20% at the lower 
limit of quantification, LLOQ), and the accuracy between 85% and 115% (80-20% at 
LLOQ). The inter-day accuracy range was 92.1% to 104.1%. The inter-day imprecision for 
the six analytes was between 4.0% and 15.6%, with poorest performance for 
dexamethasone (15.6%). An isotope labelled internal standard specific for dexamethasone 
may be required to obtain a more precise quantification of this compound. The lower limits 
of quantification, LLOQs (i.e. the lowest concentration with CV<20% and accuracy within 
80-120%), were sufficient for application in pharmacokinetic studies, ranging from 1.5 to 
4.0 μg/L, covering the low concentrations in a dosing interval. 
A frequent problem in mass spectrometry is matrix effects. Matrix effects are 
changes in the ionization efficiency in the presence of co-eluting components in the 
electrospray interface, either from the biological matrix (e.g. phospholipids), sample 
components (e.g. salts, surfactants), xenobiotics or additives in the mobile phase.133,134 
This results in either ion suppression or ion enhancement. It has been demonstrated that the 
main cause of ion suppression is a change in the droplet solution properties in the presence 
of non-volatile solutes in the electrospray ionization of the analytes.135 The chemical 
properties of the compounds are important for causing ion suppression. Molecules with 
high molecular weight are likely to suppress smaller molecules, while polar compounds are 
more prone to ion suppression than non-polar.136 Matrix effects have an impact on the 
performance of the mass spectrometer, and might affect the accuracy, precision and the 
lower limit of quantification of the assay. This emphasizes the need for investigation of 
matrix effects when developing mass spectrometry assays. According to the FDA 
bioanalytical validation guidelines, the validation of matrix effects are mandatory, but no 
procedure has been specified.130 There are two established methods for evaluation of the 
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significance of the matrix effects: post-extraction addition and post-column infusion, 
which are quantitative and qualitative approaches, respectively.136-138 In mass spectrometry 
matrix effects are unavoidable, but an adequate sample preparation and chromatography 
and the use of isotope labelled internal standard may minimize their impact. Paper I 
presents validation of matrix effect using both approaches. The results from the matrix 
effect validation in this paper show that there is substantial ion suppression, but this is 
corrected by the internal standards and does not affect the performance of the assay. 
Ideally, each analyte should have its respective isotope labelled internal standard 
for optimal quantification. Addition of compounds to the assay affected the data sampling 
and resolution, resulting in fewer data points for each chromatographic peak. As a 
compromise the compounds with similar retention time and molecular structure had a 
common internal standard (prednisolone-cortisol, prednisone-cortisone). Dividing the data 
sampling into time segments further improved the resolution. Another problem with 
introducing more internal standards is the interferences between compounds in a narrow 
m/z (mass over charge) range with closely resembling molecular weight, chemical 
properties and fragmentation patterns.  
This assay presents some limitations. The sample preparation (liquid liquid 
extraction) is quite laborious and time consuming, and includes some use of organic 
extraction solvents. The sample volume required for analysis is relatively large (500 μL). 
Smaller volumes were tested, but to achieve adequate signal intensity in the mass 
spectrometer this volume was necessary. In addition, the extracted sample had to be 
evaporated under nitrogen for further up-concentration and improvement in signal 
intensity. The analysis run time for each sample is 12 minutes, which in daily routine 
analysis is relative long. This was required to achieve chromatographic separation of 
analytes with similar m/z and fragmentation to avoid analytical interferences and cross-
talk. With more sensitive instrumentation, this method might have been optimized, with 
shorter run-time, smaller sample volumes and potential for automation. Retrospectively, 
another extraction procedure (e.g. solid phase extraction) might have been chosen to avoid 
organic solvents. 
So far, quantification of these glucocorticoids is not performed on a routinely basis, 
but for research purposes only. In pharmacokinetic studies, the assay determines all 
relevant concentrations in a dosing interval after administrations of these glucocorticoids. 
For this application, the assay performance was satisfactory. 
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4.2 Paper II 
The glucocorticoid pharmacokinetics of 16 liver transplant recipients was studied with up 
to four 12-hour dosing intervals (period I-IV) within the first three weeks after 
transplantation. The intra- and inter-individual variability in prednisolone and prednisone 
pharmacokinetics was large in this liver transplant population. There were significant 
increases in dose per body weight (dose/BW) adjusted AUC0-∞ from period I to period II, 
III and IV for both prednisolone (median 5222, 6957, 8665 and 7660 μg*h/L/(mg/kg), 
respectively) and prednisone (495, 824, 897 and 782 μg*h/L/(mg/kg), respectively). The 
median dose/BW adjusted C0 for prednisolone were 336, 258, 544 and 252 μg/L/(mg/kg) 
in period I, II, III and IV, respectively. The elimination half-lives of prednisolone were 
stable in the four periods, ranging from 3.2 to 3.6 hours. Median volume of distribution 
(VD) of prednisolone was 78, 50, 49 and 47 L in period I to IV, respectively. The 
increments in exposure were reflected in a significant reduction in apparent clearance 
(Cl/F) of prednisolone between the same periods (median 14.8, 11.5, 9.6 and 8.8 L/h, 
respectively). The median elimination rate was constant during the follow-up periods, and 
hence the elimination half-life. As Cl = VD*ke one can assume that the body weight 
adjusted apparent volume of distribution (VD/F) declined in a similar manner as the 
apparent clearance (Cl/F). These findings might indicate that the variable AUC0-∞ may be 
caused by changes in bioavailability or the distribution volume.  
In a previous study, large inter-individual variability in prednisolone 
pharmacokinetics was also found in young patients with systemic lupus erythematosus 
(SLE).139 Full 9-hour PK profiles were analysed in 8 SLE patients. Mean prednisolone 
dose/BW adjusted AUC0-9 were 4361 ng*h/L/(mg/kg) (range 1136-9580). They also 
demonstrated a correlation between prednisolone pharmacokinetics and clinical effect. 
Prednisolone Cl/F and VD were significantly lower in cushingoid patients than non-
cushingoid. Another pharmacokinetic study of prednisolone was performed in lung 
transplant recipients.140 Prednisolone exposure in 52 lung transplant recipients was 
measured by six hours AUC. This study population show wide inter-individual variation, 
with a significant increase in AUC/mg in patient with cystic fibrosis (511±82 
nmol*h/L/mg) compared to non-cystic fibrosis patients (349±27 nmol*h/L/mg). 
Furthermore, they reported that female patients had a significantly higher AUC0-6 than 
male patients. Taken all this together, the pharmacokinetics of prednisolone is highly 
variable between individuals in several patient populations, including the liver transplant 
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population reported in this paper. In addition, there are differences in prednisolone 
pharmacokinetics between genders. This may indicate a need for a more individualized 
dosing of glucocorticoids. 
A non-linear reduction of prednisolone protein binding from 95% to 60-70% when 
the serum concentration increases from 200 to 800 μg/L has been reported.7 Prednisolone 
is bound in plasma to corticosteroid binding globulin (CBG) with a high affinity and low 
capacity, and to albumin with low affinity and high capacity.6 This results in a saturation of 
the CBG and a higher free fraction of the drug when total concentration increases. An 
elevated free concentration will result in an increased elimination. The glucocorticoid 
doses administered the following days post-transplant resulted in maximum concentrations 
in this non-linear range of CBG binding in this study, which complicates the interpretation 
of the pharmacokinetic data. Measurements of the free concentration of the glucocorticoids 
could add further information, in order to investigate whether the increases in dose-BW-
adjusted AUC also is a result of an increased clearance due to a potential increase in free 
fraction. Although the free fraction was not measured, one may assume that reduced 
protein binding contributed to the higher VD/F and Cl/F and thereby to the lower dose-BW-
adjusted AUC0-∞ and Cmax in the first period after transplantation. According to this 
interpretation, one might speculate if a moderate initial dose of prednisolone, which gives 
concentrations within the linear range of CBG binding, could be equally effective with a 
reduced incidence of adverse effects due to lower unbound concentration. 
As the plasma proteins albumin and CBG are both synthesized in the hepatocytes, 
the protein synthesis is dependent of the liver function after transplantation. Table 2 
summarizes biochemical parameters in the study population, where the median albumin 
concentrations were below the lower reference limit in the four follow-up periods, with a 
gradually increase with time. The increasing albumin concentrations with time after 
transplantation might reflect the ability of the liver to synthesize protein, and may also 
affect the CBG synthesis. Increasing concentrations of CBG will affect the capacity to bind 
glucocorticoids and thereby the free fraction and clearance. In this study the CBG levels 
were not monitored, but it could add further information. One might speculate if the CBG 
concentrations could be a part of the explanation why the dose-adjusted exposure of 
prednisolone and prednisone increased during the post-operative phase. 
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 Follow-up period 
 I II III IV 
Albumin (g/L) 29 
(20-36) 
30 
(23-37) 
32 
(28-40) 
36 
(25-40) 
Total bilirubin (μmol/L) 17 
(4-137) 
15 
(7-55) 
12 
(7-67) 
11 
(7-34) 
Aspartate aminotransferase 
(IU/L) 
75 
(29-487) 
43 
(19-74) 
18 
(8-62) 
17 
(10-37) 
Alanine aminotransferase 
(IU/L) 
363 
(72-1136) 
178 
(50-428) 
81 
(22-270) 
35 
(20-198) 
 
Table 2. Biochemical parameters (serum) in period I-IV in the study population (n=16). 
Data given as median (range). Reference intervals in serum: albumin (36-48 g/L), total 
bilrubin (5-25 μmol/L) aspartate aminotransferase (women: 10-35 IU/L, men: 10-45 IU/L) 
and alanine aminotransferase (women: 10-45 IU/L, men: 10-70 IU/L).141 
 
The median ratio of the AUC of prednisolone versus prednisone was stable through the 
four periods (range 9.2 to 10.1). Compared to the median ratio, one of the sixteen patients 
had a consistently higher ratio in period I, II and III (missed period IV), with ratios of 15.2, 
24.2 and 52.7. The latter was in the presence of methylprednisolone administration. In this 
case an intravenous bolus dose (500 mg) of methylprednisolone influenced the relationship 
between prednisolone and prednisone by suppressing the plasma concentration of 
prednisone, resulting in an increased AUC0-∞ ratio (52.7). This phenomenon was seen at all 
follow-up days where methylprednisolone was administered. This patient also had a 
consistently higher ratio than median, even in the absence of methylprednisolone. The 
marked reduction in prednisone concentration coincided with high methylprednisolone 
concentrations. One explanation may be a saturation of 11β-HSD2, perhaps combined with 
an unsaturated 11β-HSD1, factors that would indicate nonlinear kinetics and increasing 
risk of adverse effects. The mechanism behind this finding and the impact of it should be 
investigated. In cases of extremely and consistently high prednisolone/prednisone ratio, 
one can speculate if genetic variants in HSD11B1 or HSD11B2, the genes encoding 11β-
HSD1 and 11β-HSD2, could be involved. This needs further investigation. 
Given the broad range of serious adverse effects and toxicity, long-term 
glucocorticoid treatment is problematic. Individual patients differ in the response to the 
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same dose of prednisone.142 In order to individualize glucocorticoid therapy a potential 
predictor of the risk of side effects could be of value. One of our hypotheses is that the 
ratio between the active prednisolone and inactive prednisone might be a potential marker 
in therapeutic drug monitoring to predict an increased risk of drug-related side effects of 
prednisolone. This study was too small and not powered and designed to establish 
significant association between ratio and side effects. The purpose was to describe the 
pharmacokinetics in this liver transplant population short-term after transplantation and to 
investigate relationship between the active and inactive forms of the glucocorticoids. As 
described in section 1.4 the expression of 11β-HSD 1 and 2 is tissue specific. A limitation 
of this ratio is that it is based on plasma concentration measurements, which does not 
necessarily reflect the prednisolone and prednisone concentrations in the various tissues. 
Whether a high or a low plasma ratio might be associated with a risk of adverse effects, 
rejection episodes or the glucocorticoid effects should be investigated. Furthermore, 
variability in the pharmacodynamics of glucocorticoids should be investigated with respect 
to the glucocorticoids receptor. Single nucleotide polymorphisms in the NR3C1, encoding 
the glucocorticoid receptor, might be a factor contributing to pharmacodynamic 
variability.143 As prednisolone is substrate for both CYP3A4, CYP3A5 and P-glycoprotein, 
genetic variants altering the expression and function of these may impact the prednisolone 
pharmacokinetics. Furthermore, synthetic glucocorticoids induce gene expression of 
CYP3A and P-gp by activation of the human pregnane X receptor (PXR). Miura et al. 
investigated the influence of polymorphisms in CYP3A5, ABCB1 (P-glycoprotein) and 
NR1I2 (PXR) genes on the prednisolone pharmacokinetics in 95 renal transplant 
recipients.144 They found that patients carrying the NR1I2 7635GG or 7635AG allele had 
significantly lower AUC0-24 and Cmax values than patients having the 7635AA allele. 
Furthermore, no significant differences in prednisolone pharmacokinetics between the 
CYP3A5*3 and CYP3A5*1 genotypes were revealed. There were no significant differences 
in prednisolone exposure between the different ABCB1 genotypes. However, the 
combination of the ABCB1 3455CC and CYP3A5*3/*3 genotypes revealed significant 
differences in mean Cmax of prednisolone, but not for the AUC0-24. Further explorations in 
the genetics affecting the pharmacokinetic variability of glucocorticoids should be 
performed in order to individualize glucocorticoid therapy. 
To our best knowledge, this is the first study investigating the relationship between 
prednisolone and prednisone pharmacokinetics. The results in this study indicate a 
potential for individualization of glucocorticoid dosing after liver transplantation. 
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However, there are examples of extreme intra-individual day-to-day variability in the early 
post-transplant phase, which highlight the challenges for implementation into clinical 
practice. In future studies, the relationship between appropriately timed concentration 
measurements and the effects of glucocorticoid treatment must be addressed.  
 
4.3 Paper III  
Tacrolimus 
The AUC0-12h for tacrolimus increased significantly from follow-up period I (day 1-5 post-
transplant) to period II (day 6-10), III (day 11-17) and IV (> 17 days). Median trough 
concentrations (C0) were 5.2, 6.5, 8.5 and 8.5 μg/L in the four periods. From period I to 
period III and IV the tacrolimus doses were doubled. The dose/BW-adjusted AUC0-12h 
increased significantly from period I to period II, III and IV. Within two weeks after 
transplantation, four patients experienced an episode of acute rejection. The pooled (period 
I-IV) median tacrolimus C0 were 6.5 μg/L and 7.9 μg/L in the non-rejection group and 
rejection group, respectively. The median tacrolimus AUC0–12h (pooled period I-IV) was 
comparable between the non-rejection group (106 μg*h/L) and the rejection group (107 
μg*h/L).  
In this study population one of the patients was heterozygous expresser of 
CYP3A5*1/*3, while 14 patients were non-expressers (CYP3A5*3/*3). The CYP3A5 
expresser was transplanted with liver graft from a donor heterozygous for CYP3A5*1/*3, 
while the other donors carried the CYP3A5*3/*3 genotype. The recipient carrying the 
CYP3A5*1/*3 variant had lower dose/BW-adjusted AUC0-12h and C0, but not outside the 
range of the non-expresser group. 
According to recently published work by De Jonge et al. the CYP3A5 genotype 
contributes to approximately 30% of the variability in tacrolimus dose requirement and 
clearance in renal transplant recipients.67 Furthermore, they describe that hematocrit 
explains additional 4-14%. In our study, the hematocrit was not investigated in terms of 
pharmacokinetic variability. Tacrolimus is most importantly metabolized by CYP3A in the 
hepatocytes. The metabolic capacity of the transplanted liver is affected by the graft 
function, which may be variable after transplantation. Lock et al. showed that the initial 
graft function after liver transplantation influences the pharmacokinetics of tacrolimus, and 
is a predictor of tacrolimus trough levels the first week after transplantation.145 An 
impaired hepatic CYP3A metabolism due to a delayed graft function post-transplant may 
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affect the systemic exposure of tacrolimus. When the metabolic capacity of the liver is 
impaired, the intestinal CYP3A4 might be of higher importance. In addition to the impact 
of graft function, the CYP3A5 genotype in liver and intestines affect the tacrolimus 
exposure and can cause variability in the tacrolimus pharmacokinetics. Recipients with a 
CYP3A5*1 carrying liver graft have a reduced concentration/dose ratio, and require a 
higher dose to reach the target concentration.146 A liver transplant recipient might receive a 
graft from a donor with a different CYP3A5 genotype, which changes the recipient’s 
metabolism post-transplant. Different CYP3A5 variants in the liver and the intestines make 
genotyping of the recipient inconclusive because the major contributor to tacrolimus 
metabolism is the hepatic CYP3A4/5. Ji et al. recently investigated the combined effect of 
the CYP3A5 genotypes in liver and intestines on the tacrolimus pharmacokinetics after 
liver transplantation.147 They found that in the early phase after transplantation, the 
CYP3A5 genotype in the native intestines was more important than the genotype in the 
transplanted liver. With time post-transplant the recipient-donor effect on the dose 
requirement changed. The benefit of pre-transplant CYP3A5 genotyping was demonstrated 
in renal transplant recipients, where the initial tacrolimus dosing was adjusted according to 
CYP3A5 genotype.148 The increased dose requirement to achieve the target trough 
concentration of tacrolimus carrying the CYP3A5*1 allele and the fact that this genotype 
explain a major part of the variability in tacrolimus pharmacokinetics, makes genotyping 
an attractive approach for further individualization of tacrolimus dosing. However, this is 
more complex in the liver transplant population since the genotype of the graft (the liver) is 
of particular importance.  
The efflux pump P-glycoprotein functions as an absorption barrier to orally 
administered drugs.149 Goto et al. investigated the relationship between the intestinal 
MDR1 mRNA expression and the CYP3A5 genotype in the grafted liver in 38 liver 
transplant recipients. They found that recipients with a high MDR1 intestinal expression 
combined with the CYP3A5*1 genotype had an increased tacrolimus dose requirement the 
first week after transplantation. 146 Thus, intestinal MDR1 mRNA expression and CYP3A5 
genotypes explain some of the varibility in tacrolimus pharmacokinetics. As described in 
section 1.8, the expression of the CYP3A and MDR1 genes is regulated by the human 
pregnane X receptor, which is activated by glucocorticoids. Due to high doses of 
prednisolone early after transplantation, induction of MDR1 and CYP3A expression may 
contribute to the relatively low tacrolimus exposure observed in the first follow-up periods 
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described in this paper. When the prednisolone doses are tapered, this induction is reduced, 
and tacrolimus exposure will increase. 
Another source of variability in the tacrolimus pharmacokinetics is the 
administration of grapefruit juice. A prospective study performed in 120 liver transplant 
recipients by Liu et al. demonstrated that co-administration of grapefruit juice increased 
the bioavailability of tacrolimus.150 In our study 0, 4, 5 and 3 patients were administered 
grapefruit juice (200 mL twice daily) in follow-up period I, II, III and IV, respectively. As 
described in section 1.8, grapefruit juice inhibits CYP3A5, and is used to increase the oral 
bioavailability of tacrolimus, hence the concentration/dose ratio. This will affect both the 
AUC0-12h and dose/body weight adjusted AUC0-12h observed in this study.  
 
Mycophenolic acid 
The medians of MPA AUC0-12h and C0 were stabile in the four follow-up periods, ranging 
from 21.9 mg*h/L to 27.8 mg*h/L and 1.2 mg/L to 1.6 mg/L, respectively. Medians of 
dose/BW-adjusted AUC0-12h and C0 were in the range 1.83-2.25 mg*h/L/(mg/kg) and 
0.094-0.116 mg/L/(mg/kg). The recommended target range of MPA AUC0–12h is suggested 
to be 30-60 mg*h/L in renal transplant recipients.120 According to this target range, 
although this study presents data from liver transplant recipients, 67%, 69%, 53% and 60% 
of the patients fell below the lower limit of the suggested target in period I, II, III and IV, 
respectively. The AUC0-12h was in the range 8.6-57.4 mg*h/L, with median in each period 
ranging from 21.9 to 27.8 mg*h/L. 
The pre-dose IMPDH activity (A0) showed high inter-individual variability, 
ranging from 2.2 to 41.2 pmol/106cells/min between individuals, with medians of 12.7, 
10.1, 11.4 and 6.4 pmol/106cells/min in period I, II, III and IV, respectively. Median 
minimum IMPDH activity (Amin) in the study population was between 2.3 and 2.9 
pmol/106cells/min (range 0.0-12.1) in the four follow-up periods. The median IMPDH 
inhibition spanned 63% and 77% (range 10-100%) in the four periods. The median pre-
transplant IMPDH activity was 14.9 pmol/106cells/min (range 9.4-40.6). Three of the 
patients showed a maximum IMPDH activity 4-fold higher within the dosing interval than 
the pre-dose concentration. One of these patients was heterozygous for the IMPDH1 SNPs 
rs227893 and rs2278294 and the IMPDH2 variant rs11706052, while one was 
homozygous for both IMPDH1 variants. The third patient was heterozygous for rs227893 
and rs11706052. These findings might indicate a potential for increasing the 
immunosuppressive effect of MPA by higher dosing, under monitoring of IMPDH activity, 
    
in selected patients. Alternatively, in patients with low degree of IMPDH inhibition, other 
immunosuppressive drugs might be considered to achieve adequate immunosuppression. 
For MPA the median AUC0–12h was comparable between the non-rejection group 
(median 25.6 mg*h/L, period I-IV pooled) and the rejection group (median 24.2 mg*h/L). 
There was a trend towards a lower degree of IMPDH inhibition in the rejection group 
(median IMPDH inhibition 64.0%, period I-IV pooled) compared to the non-rejection 
group (median IMPDH inhibition 73.0%). 
Although the median MPA exposure and pre-dose concentrations were stable 
during the four periods, considerable variability was observed between the patients. This 
inter-individual variability in MPA pharmacokinetics was consistent with findings in other 
studies.151-155 In the study performed by Jain et al. in eight liver transplant recipients, the 
median MPA AUC0-12h of 32.3 mg*h/L (range 7.3-102) was reported in the first month 
post-transplant.153 Brunet et al. found that the MPA exposure was relatively low in 15 liver 
transplant recipients during the first month after transplantation.151 They further 
demonstrated variable exposure of MPA, with median AUC0-12h of 17.4 mg*h/L (day 6 
post-transplant, range 13.2-39.7), 16.3 mg*h/L (day 10, range 8.4-51.3), 26.3 mg*h/L (day 
16, range 13.1-45.8) and 33.6 mg*h/L (month 3, range 15.1-54.6). The proportion of 
patients below the target range (30-60 mg*h/L) of AUC0-12h was 85%, 92%, 64% and 30% 
at day 6, 10, 16 and month 3, respectively. Pisupati et al. observed large pharmacokinetic 
variability in ten patients at three time points during the first six weeks post-transplant, 
with MPA AUC0-12h (mean± SD) of 50.8±42.1 mg*h/L (≤ 1week), 60.3±38.5 mg*h/L (> 1 
week and ≤ 2 weeks) and 118.0±57.6 mg*h/L (≥ 1 week and ≤ 6 weeks).154 The MPA 
exposure described by Pisupati et al. was generally higher than reported by Jain, Brunet 
and in our study, where the mean AUC0-12h was within and above the recommended target 
area. However, a large proportion of the liver transplant patients were reported to reach 
sub-therapeutic levels of MPA short-term after transplantation.  
There are several possible explanations for the observed low MPA exposure in the 
early phase after liver transplantation. The absorption might be reduced in the early post-
operative phase. Anaesthesia and surgical trauma can cause impairment of gastric motility 
and the absorption of orally administered drugs.156,157 A second explanation might be an 
increased clearance short-term after transplantation. An earlier study found that the oral 
bioavailability of MPA in the immediate phase after liver transplantation was less than 
50%, and that an increase in pre-dose concentration and exposure was associated with 
increasing plasma albumin concentration.158 These findings were consistent with the 
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findings of our study, (see section 4.2 for biochemical data). MPA is highly bound to 
albumin and is a low clearance drug. Thus the clearance of MPA will be affected by the 
degree of protein binding and plasma albumin levels. Benichou et al. report that the 
variability in free MPA exposure was much higher than that of total MPA exposure in the 
immediate phase after liver transplantation.159 An increased risk of leukopenia has been 
reported for total MPA AUC0-12h above 40 mg*h/L within 2 weeks after liver 
transplantation.152 Although the MPA exposure was in the recommended target range, this 
does not necessarily reflect the free concentration. Hence patients with impaired hepatic or 
renal function, liver transplant recipients or patients with hypoalbumineamia might benefit 
from free drug measurement.  
As described in section 1.6, the UGT1A9 sequence variants -275T>A and -
2152C>T cause higher UGT1A9 expression and increased MPA glucuronidation, resulting 
in a lower MPA exposure. In the study population decribed in this paper one patient was 
heterozygous for both -275T>A and -2152C>T, the rest carried the wild-type alleles. For 
the sequence variants -440C>T and -331T>C seven patients were heterozygous and one 
homozygous for both. In this small group of recipients there were no significant 
associations between UGT variants and the variability in AUC0–12h and C0. In another, 
larger study of renal transplant recipients, carriers of -275T>A and/or -2152C>T variants 
had lower MPA AUC0-12h.89 As for the CYP3A5 genotyping in liver transplant recipients, 
the liver specific expression makes the interpretation of UGT variants difficult, hence both 
donor and recipient must be genotyped. Moreover, the UGT1A9 variants -275T>A 
and -2152C>T increase the MPA glucuronidation, while the –440C>T and –331T>C 
variants decrease it. Measurement of the metabolite MPAG might help describing the 
overall effect of UGT1A9 sequence variants. 
 A close, inverse association between MPA plasma concentration and IMPDH 
activity after oral MMF administration has been demonstrated.108,160-163 Glander et al. 
demonstrated large variability in pre-transplant IMPDH activity between individuals, and a 
poor correlation between pre-dose MPA concentration and IMPDH activity.108 As 
described in section 1.6, IMPDH variants are associated with episodes of acute rejection 
and the presence of an IMPDH2 3757T>C allele is associated with increased IMPDH 
activity in renal transplant recipients.105-107 Bremer et al. demonstrated that the IMPDH 
expression in lymphocytes increased early after transplantation, and that increased 
IMPDH2 expression is associated with acute rejection in renal transplant recipients. 103 
High pre-transplant IMPDH activity is also associated with rejection. 108 In liver transplant 
    

recipients, patients with MPA-related side effects tended to have a higher level of 
IMPDH2 expression.164 
 
Individualizing mycophenolic acid therapy 
In our study material, the tacrolimus exposure is generally low in the first study period. 
The low exposure is followed by an increase in tacrolimus dosing in order to reach target 
concentrations. As described in section 1.8 the initial low tacrolimus concentrations might 
reflect the clinical management of renal function in the early post-operative period (period 
I and II). This relatively low dosing of tacrolimus immediately after transplantation is in a 
period where the risk of acute rejection is the greatest. Maintaining adequate 
immunosuppression in this period is crucial to avoid rejection episodes. The efficacy of 
MPA (i.e. IMPDH inhibition) might be of great importance in this period. In order to 
ensure adequate immunosuppression in the early-phase after transplantation, PD-
monitoring of MPA in combination with PK monitoring of tacrolimus and MPA might be 
valuable. Several complications and serious adverse effects have been described for 
calcineurin inhibitors (CNI), where nephrotoxicity is of big concern.165 As mycophenolic 
acid is not associated with impairment in renal function, the combination of reduced CNI 
dosing and concentration controlled MPA dosing is an attractive approach. Assisted by 
therapeutic drug monitoring, an increased dosing of MPA could provide a more adequate 
immunosuppression in selected patients in the early post-operative phase. As a result, a 
more moderate dosing of calcineurin inhibitors (e.g. tacrolimus) might be considered to 
avoid CNI-induced nephrotoxicity. The Opticept® trial revealed that the combination of 
low-dose CNI and concentration-controlled dosing of MMF was not inferior to fixed MMF 
and standard tacrolimus dosing in renal transplant recipients, with treatment failure as the 
end point.166  
 Pharmacodynamic (PD) monitoring and pharmacogenetics, might in a combination 
with more conventional pharmacokinetic (PK) monitoring describe the overall MPA 
response better than PK monitoring alone. To allow reductions of CNI and steroid dosing, 
PD monitoring may enable a closer follow-up of the patients, while ensuring adequate 
immunosuppression. However, there are some limitations in the pharmacodynamic 
monitoring approach. The most suitable marker (e.g. pre-dose or minimum IMPDH 
activity, degree of inhibition) for MPA efficacy must be further elucidated. A therapeutic 
range of IMPDH activity must be established. Furthermore, the time point after MPA dose 
for sampling must be decided. In our study, the time for maximum IMPDH inhibition 
    
(Tmin) ranged from 0.5 to 10 hours between individuals (medians between 1.0 and 2.0 
hours in the four periods), so finding the appropriate sampling time point is challenging. 
The matrix for measuring the IMPDH activity must be standardized (e.g. whole blood, 
mononuclear cells or CD4+ cells). Available assays for quantification of IMPDH activity 
is quite time consuming and laborious, which limits the implementation of PD monitoring 
in the daily routine. Even though using IMPDH activity as a biomarker for the 
pharmacological effect of MPA is promising, further investigation is needed to ensure its 
validity. Larger, prospective studies addressing the PK-PD relationship must be performed. 
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
Conclusion of thesis 
Given the role of the liver in the pharmacokinetics of drugs and all the potential factors 
leading to individual variability in immunosuppressive therapy, the present thesis aimed to 
describe the pharmacokinetics of glucocorticoids, tacrolimus and mycophenolic acid in the 
first weeks after liver transplantation. Furthermore, the pharmacodynamics of 
mycophenolic acid was investigated in addition to relevant genetic analyses. 
An LC-MS/MS method was developed for quantification of prednisolone, 
prednisone, cortisol, cortisone, methylprednisolone and dexamethasone in human plasma, 
which is applicable for pharmacokinetic studies. The assay was validated and was in 
accordance with the bioanalytical guidelines from U.S. Food and Drug Administration 
(FDA). In addition, matrix effects were validated qualitatively and quantitatively, and were 
satisfactory.  
Large intra- and inter-individual variability was observed in the pharmacokinetics 
of prednisolone and prednisone in adult liver transplant recipients. Dose per body weight 
adjusted exposure of prednisolone increased significantly during the follow-up periods. A 
significant decrease in apparent clearance (CL/F) combined with a reduction in the 
apparent volume of distribution (VD/F) indicate that the bioavailability (F) increased with 
time after transplantation. The ratio between pharmacologically active prednisolone and 
inactive prednisone were generally stable throughout the study periods, but one patient had 
markedly elevated ratios in all periods, compared to the population medians. In patients 
receiving methylprednisolone intravenously, the prednisone concentrations in plasma 
decreased with a subsequent increase in this ratio. The mechanism behind this finding (e.g. 
sequence variants in HSD11B1 and HSD11B2) contributing to this elevated ratio should be 
further investigated. 
In parallel to the findings for prednisolone and prednisone, the intra- and inter-
individual variability of tacrolimus pharmacokinetics was large in the same study 
population. The tacrolimus exposure was relative low the first week after transplantation, 
with significant increases in dose per bodyweight adjusted AUC0-12h from period I to the 
following periods. In order to attain the target C0-concentrations the median tacrolimus 
dose was doubled from period I to period III-IV. 
 
    
A trend towards a lower degree of IMPDH inhibition was observed in the patient with 
episodes of acute rejection, compared to the patients without rejection episodes. More than 
50% of the patients fell below the suggested target range for MPA exposure (30-60 
mg*h/L) in all four follow-up periods, suggesting that the initial dose might be too low the 
first days post-transplant in some of the patients. Pharmacodynamic monitoring of MPA, 
by measuring IMPDH activity, may assist in identifying patients with a suboptimal effect 
of MPA. 
The overall conclusion of this thesis is that in the adult liver transplant population, 
short-term after transplantation, the intra- and inter-individual variability in the 
pharmacokinetics of immunosuppressive drugs is large. As a consequence, a significant 
proportion of patients may be at sub-therapeutic immunosuppression in a period when the 
risk of acute rejection episodes is highest. The factors responsible for this variability must 
be further addressed and taken into account in order to further individualize the dosing of 
these immunosuppressive drugs. 
    
Future perspectives 
To add further knowledge to individualization of glucocorticoid therapy, future 
investigations should include studies in other populations (i.e. other patients and healthy 
volunteers). Studies investigating the glucocorticoid pharmacokinetics in healthy 
volunteers and in children with acute lymphatic leukaemia and in paediatric transplanted 
recipients have been initiated by our group. Further research is needed to determine if there 
is a rationale for therapeutic drug monitoring of glucocorticoids. A possible association 
between the prednisolone/prednisone ratio and risk of adverse effects should be 
investigated, whether the ratio can predict the risk of glucocorticoid related side effects or 
not. Future studies must address the relationship between appropriately timed 
concentration measurements, and the effects of glucocorticoid treatment of organ 
transplant recipients. Rejection, graft loss, patient survival and adverse effects should be 
addressed as end-points in such a prospective study, due to the serious side effect profile of 
glucocorticoids. Measuring the unbound concentrations of glucocorticoids should be 
explored, due to the dose-dependent non-linear protein binding in plasma, which affects 
the biological active fraction available. With regards to the pre-receptor metabolism of 
glucocorticoids, sequence variants of 11β-HSD should be determined to see whether there 
is an association between these variants and the pharmacokinetics. The future of 
pharmacodynamic monitoring of mycophenolic acid relies on larger prospective studies to 
find monitoring strategies with regards to suitable time points for sampling, sampling 
material and therapeutic ranges for IMPDH activity. To further investigate the effect of the 
UGT1A9 sequence variants on MPA pharmacokinetics, quantification of the metabolite 
MPAG should be performed. 
    
References 
 1.  Starzl TE, Groth CG, Brettschneider L, et al. Orthotopic homotransplantation of the 
human liver. Ann Surg. 1968;168:392-415. 
 2.  Millard CE. The NIH Consensus Development Conference on liver transplantation. 
R I Med J. 1984;67:69-71. 
 3.  Aberg F, Isoniemi H, Hockerstedt K. Long-term results of liver transplantation. 
Scand J Surg. 2011;100:14-21. 
 4.  Starzl TE, Ishikawa M, Putnam CW, et al. Progress in and deterrents to orthotopic 
liver transplantation, with special reference to survival, resistance to hyperacute 
rejection, and biliary duct reconstruction. Transplant Proc. 1974;6:129-139. 
 5.  Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft 
nephropathy. N Engl J Med. 2003;349:2326-2333. 
 6.  Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of 
systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98. 
 7.  Boudinot FD, Jusko WJ. Plasma protein binding interaction of prednisone and 
prednisolone. J Steroid Biochem. 1984;21:337-339. 
 8.  Hammer F, Stewart PM. Cortisol metabolism in hypertension. Best Pract Res Clin 
Endocrinol Metab. 2006;20:337-353. 
 9.  Amelung D, Hubener HJ, Roka L, et al. Conversion of cortisone to compound F. J 
Clin Endocrinol Metab. 1953;13:1125-1126. 
 10.  Bujalska IJ, Draper N, Michailidou Z, et al. Hexose-6-phosphate dehydrogenase 
confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1. 
J Mol Endocrinol. 2005;34:675-684. 
 11.  Odermatt A, Arnold P, Stauffer A, et al. The N-terminal anchor sequences of 
11beta-hydroxysteroid dehydrogenases determine their orientation in the 
endoplasmic reticulum membrane. J Biol Chem. 1999;274:28762-28770. 
    
 12.  Agarwal AK, Mune T, Monder C, et al. NAD(+)-dependent isoform of 11 beta-
hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep 
kidney. J Biol Chem. 1994;269:25959-25962. 
 13.  Diederich S, Eigendorff E, Burkhardt P, et al. 11beta-hydroxysteroid 
dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the 
activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab. 
2002;87:5695-5701. 
 14.  Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of 
type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol 
Metab. 1998;83:1325-1335. 
 15.  Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid 
dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. 
Endocr Rev. 2004;25:831-866. 
 16.  Edwards CR, Stewart PM, Burt D, et al. Localisation of 11 beta-hydroxysteroid 
dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet. 
1988;2:986-989. 
 17.  Osinski PA. Steroid 11beta-ol dehydrogenase in human placenta. Nature. 
1960;187:777. 
 18.  Roland BL, Funder JW. Localization of 11beta-hydroxysteroid dehydrogenase type 
2 in rat tissues: in situ studies. Endocrinology. 1996;137:1123-1128. 
 19.  Stewart PM. 11 beta-Hydroxysteroid dehydrogenase: implications for clinical 
medicine. Clin Endocrinol (Oxf). 1996;44:493-499. 
 20.  Whorwood CB, Ricketts ML, Stewart PM. Epithelial cell localization of type 2 11 
beta-hydroxysteroid dehydrogenase in rat and human colon. Endocrinology. 
1994;135:2533-2541. 
 21.  Tannin GM, Agarwal AK, Monder C, et al. The human gene for 11 beta-
hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal 
localization. J Biol Chem. 1991;266:16653-16658. 
    
 22.  Albiston AL, Obeyesekere VR, Smith RE, et al. Cloning and tissue distribution of 
the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell 
Endocrinol. 1994;105:R11-R17. 
 23.  Agarwal AK, Rogerson FM, Mune T, et al. Gene structure and chromosomal 
localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 
11 beta-hydroxysteroid dehydrogenase. Genomics. 1995;29:195-199. 
 24.  Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: 
Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in 
transgenic mice. Proc Natl Acad Sci U S A. 2004;101:7088-7093. 
 25.  Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity 
and the metabolic syndrome. Science. 2001;294:2166-2170. 
 26.  Walker BR, Connacher AA, Lindsay RM, et al. Carbenoxolone increases hepatic 
insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing 
glucocorticoid receptor activation. J Clin Endocrinol Metab. 1995;80:3155-3159. 
 27.  Draper N, Walker EA, Bujalska IJ, et al. Mutations in the genes encoding 11beta-
hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase 
interact to cause cortisone reductase deficiency. Nat Genet. 2003;34:434-439. 
 28.  Franks PW, Knowler WC, Nair S, et al. Interaction between an 11betaHSD1 gene 
variant and birth era modifies the risk of hypertension in Pima Indians. 
Hypertension. 2004;44:681-688. 
 29.  Nair S, Lee YH, Lindsay RS, et al. 11beta-Hydroxysteroid dehydrogenase Type 1: 
genetic polymorphisms are associated with Type 2 diabetes in Pima Indians 
independently of obesity and expression in adipocyte and muscle. Diabetologia. 
2004;47:1088-1095. 
 30.  Morales MA, Carvajal CA, Ortiz E, et al. [Possible pathogenetic role of 11 beta-
hydroxysteroid dehydrogenase type 1 (11betaHSD1) gene polymorphisms in 
arterial hypertension]. Rev Med Chil. 2008;136:701-710. 
    
 31.  Gambineri A, Tomassoni F, Munarini A, et al. A combination of polymorphisms in 
HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome 
in women with and without polycystic ovary syndrome. Eur J Endocrinol. 
2011;165:283-292. 
 32.  Malavasi EL, Kelly V, Nath N, et al. Functional Effects of Polymorphisms in the 
Human Gene Encoding 11{beta}-Hydroxysteroid Dehydrogenase Type 1 
(11{beta}-HSD1): A Sequence Variant at the Translation Start of 11{beta}-HSD1 
Alters Enzyme Levels. Endocrinology. 2009. 
 33.  Campino C, Carvajal CA, Cornejo J, et al. 11beta-Hydroxysteroid dehydrogenase 
type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities 
in the pathogenia of essential hypertension. Endocrine. 2010;37:106-114. 
 34.  Brand E, Kato N, Chatelain N, et al. Structural analysis and evaluation of the 
11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human 
essential hypertension. J Hypertens. 1998;16:1627-1633. 
 35.  Williams TA, Mulatero P, Filigheddu F, et al. Role of HSD11B2 polymorphisms in 
essential hypertension and the diuretic response to thiazides. Kidney Int. 
2005;67:631-637. 
 36.  Mariniello B, Ronconi V, Sardu C, et al. Analysis of the 11beta-hydroxysteroid 
dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J 
Hypertens. 2005;18:1091-1098. 
 37.  Campino C, Quinteros H, Owen GI, et al. 11beta-hydroxysteroid dehydrogenase 
type 2 polymorphisms and activity in a Chilean essential hypertensive and 
normotensive cohort. Am J Hypertens. 2012;25:597-603. 
 38.  Wilson RC, Krozowski ZS, Li K, et al. A mutation in the HSD11B2 gene in a 
family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 
1995;80:2263-2266. 
 39.  Mune T, Rogerson FM, Nikkila H, et al. Human hypertension caused by mutations 
in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 
1995;10:394-399. 
    	
 40.  Draper N, Stewart PM. 11beta-hydroxysteroid dehydrogenase and the pre-receptor 
regulation of corticosteroid hormone action. J Endocrinol. 2005;186:251-271. 
 41.  Wright AP, Zilliacus J, McEwan IJ, et al. Structure and function of the 
glucocorticoid receptor. J Steroid Biochem Mol Biol. 1993;47:11-19. 
 42.  McCoy CE, Carpenter S, Palsson-McDermott EM, et al. Glucocorticoids inhibit 
IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 
activation. J Biol Chem. 2008;283:14277-14285. 
 43.  Charron J, Drouin J. Glucocorticoid inhibition of transcription from episomal 
proopiomelanocortin gene promoter. Proc Natl Acad Sci U S A. 1986;83:8903-
8907. 
 44.  Whiting KP, Restall CJ, Brain PF. Steroid hormone-induced effects on membrane 
fluidity and their potential roles in non-genomic mechanisms. Life Sci. 
2000;67:743-757. 
 45.  Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of 
a functional human glucocorticoid receptor cDNA. Nature. 1985;318:635-641. 
 46.  Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid receptor isoforms and 
mechanisms of post-translational modification. J Steroid Biochem Mol Biol. 
2006;102:11-21. 
 47.  Huizenga NA, Koper JW, De Lange P, et al. A polymorphism in the glucocorticoid 
receptor gene may be associated with and increased sensitivity to glucocorticoids in 
vivo. J Clin Endocrinol Metab. 1998;83:144-151. 
 48.  Bray PJ, Cotton RG. Variations of the human glucocorticoid receptor gene 
(NR3C1): pathological and in vitro mutations and polymorphisms. Hum Mutat. 
2003;21:557-568. 
 49.  Bronnegard M, Stierna P, Marcus C. Glucocorticoid resistant syndromes--
molecular basis and clinical presentations. J Neuroendocrinol. 1996;8:405-415. 
    

 50.  Siekierka JJ, Staruch MJ, Hung SH, et al. FK-506, a potent novel 
immunosuppressive agent, binds to a cytosolic protein which is distinct from the 
cyclosporin A-binding protein, cyclophilin. J Immunol. 1989;143:1580-1583. 
 51.  Handschumacher RE, Harding MW, Rice J, et al. Cyclophilin: a specific cytosolic 
binding protein for cyclosporin A. Science. 1984;226:544-547. 
 52.  Shaw KT, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid 
dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc 
Natl Acad Sci U S A. 1995;92:11205-11209. 
 53.  Wallemacq PE, Furlan V, Moller A, et al. Pharmacokinetics of tacrolimus (FK506) 
in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet. 
1998;23:367-370. 
 54.  Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of 
tacrolimus. Clin Pharmacokinet. 1995;29:404-430. 
 55.  Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports 
cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080. 
 56.  Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on 
tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34:836-847. 
 57.  Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro 
hepatic clearance of tacrolimus. Clin Chem. 2005;51:1374-1381. 
 58.  Moller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-labeled 
tacrolimus after intravenous and oral administration in healthy human subjects. 
Drug Metab Dispos. 1999;27:633-636. 
 59.  Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human 
CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2012. 
 60.  Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome 
P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 
1998;87:1322-1330. 
    
 61.  Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and 
intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol 
Exp Ther. 1997;283:1552-1562. 
 62.  Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of 
tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623-653. 
 63.  Anglicheau D, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms 
and immunosuppressive drugs: an update. Pharmacogenomics. 2007;8:835-849. 
 64.  Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible 
consequences. Pharmacogenomics. 2004;5:243-272. 
 65.  Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and 
characterization of the genetic basis of polymorphic CYP3A5 expression. Nat 
Genet. 2001;27:383-391. 
 66.  van Schaik RH, van dH, I, van den Anker JN, et al. CYP3A5 variant allele 
frequencies in Dutch Caucasians. Clin Chem. 2002;48:1668-1671. 
 67.  de JH, de LH, Verbeke K, et al. In Vivo CYP3A4 Activity, CYP3A5 Genotype, 
and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal 
Transplant Patients. Clin Pharmacol Ther. 2012;92:366-375. 
 68.  Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are 
responsible for biotransformation of FK506 and rapamycin in man and rat. Drug 
Metab Dispos. 1992;20:753-761. 
 69.  Lampen A, Christians U, Gonschior AK, et al. Metabolism of the macrolide 
immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J 
Pharmacol. 1996;117:1730-1734. 
 70.  Tada H, Tsuchiya N, Satoh S, et al. Impact of CYP3A5 and MDR1(ABCB1) 
C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant 
recipients. Transplant Proc. 2005;37:1730-1732. 
    
 71.  Pichard L, Fabre I, Daujat M, et al. Effect of corticosteroids on the expression of 
cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of 
human hepatocytes. Mol Pharmacol. 1992;41:1047-1055. 
 72.  Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) 
in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol 
Ther. 1997;62:248-260. 
 73.  Maezono S, Sugimoto K, Sakamoto K, et al. Elevated blood concentrations of 
calcineurin inhibitors during diarrheal episode in pediatric liver transplant 
recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-
glycoprotein. Pediatr Transplant. 2005;9:315-323. 
 74.  Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of 
mycophenolate mofetil in healthy subjects after single-dose oral and intravenous 
administration. J Clin Pharmacol. 1996;36:315-324. 
 75.  Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, 
tolerability, and pharmacokinetics. Clin Transplant. 2000;14:179-188. 
 76.  Ensom MH, Partovi N, Decarie D, et al. Pharmacokinetics and protein binding of 
mycophenolic acid in stable lung transplant recipients. Ther Drug Monit. 
2002;24:310-314. 
 77.  Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of 
mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 
2007;46:13-58. 
 78.  Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic 
acid (MPA) and determinants of MPA free fraction in pediatric and adult renal 
transplant recipients. German Study group on Mycophenolate Mofetil Therapy in 
Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998;9:1511-1520. 
 79.  Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium 
delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin 
Transplant. 2005;19:199-206. 
    
 80.  Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of 
mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455. 
 81.  Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human 
liver, kidney and jejunum microsomes. Br J Clin Pharmacol. 2001;52:605-609. 
 82.  Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-
glucuronosyltransferase isoforms involved in mycophenolic acid phase II 
metabolism. Drug Metab Dispos. 2005;33:139-146. 
 83.  Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with 
mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am 
J Transplant. 2005;5:987-994. 
 84.  Schutz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically 
active metabolite of mycophenolic acid in plasma of transplant recipients treated 
with mycophenolate mofetil. Clin Chem. 1999;45:419-422. 
 85.  Davies NM, Grinyo J, Heading R, et al. Gastrointestinal side effects of 
mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial 
Transplant. 2007;22:2440-2448. 
 86.  Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and 
carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of 
transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 
1999;126:1075-1082. 
 87.  Johnson LA, Oetting WS, Basu S, et al. Pharmacogenetic effect of the UGT 
polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur J Clin 
Pharmacol. 2008;64:1047-1056. 
 88.  Kuypers DR, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-
glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide 
polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval 
exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351-
361. 
    
 89.  Kuypers DR, de Jonge H, Naesens M, et al. Current target ranges of mycophenolic 
acid exposure and drug-related adverse events: a 5-year, open-label, prospective, 
clinical follow-up study in renal allograft recipients. Clin Ther. 2008;30:673-683. 
 90.  van Schaik RH, van Agteren M, de Fijter JW, et al. UGT1A9 -275T>A/-2152C>T 
polymorphisms correlate with low MPA exposure and acute rejection in 
MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 
2009;86:319-327. 
 91.  Sanchez-Fructuoso AI, Maestro ML, Calvo N, et al. The prevalence of uridine 
diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-
nucleotide polymorphisms T-275A and C-2152T and its influence on 
mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant 
Proc. 2009;41:2313-2316. 
 92.  Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in 
the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity 
levels are strongly genetically controlled in the liver. Pharmacogenetics. 
2004;14:501-515. 
 93.  Cattaneo D, Baldelli S, Perico N. Pharmacogenetics of immunosuppressants: 
progress, pitfalls and promises. Am J Transplant. 2008;8:1374-1383. 
 94.  Baldelli S, Merlini S, Perico N, et al. C-440T/T-331C polymorphisms in the 
UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney 
transplantation. Pharmacogenomics. 2007;8:1127-1141. 
 95.  Levesque E, Delage R, oit-Biancamano MO, et al. The impact of UGT1A8, 
UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of 
mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol 
Ther. 2007;81:392-400. 
 96.  Prausa SE, Fukuda T, Maseck D, et al. UGT genotype may contribute to adverse 
events following medication with mycophenolate mofetil in pediatric kidney 
transplant recipients. Clin Pharmacol Ther. 2009;85:495-500. 
    
 97.  Zimmermann AG, Gu JJ, Laliberte J, et al. Inosine-5'-monophosphate 
dehydrogenase: regulation of expression and role in cellular proliferation and T 
lymphocyte activation. Prog Nucleic Acid Res Mol Biol. 1998;61:181-209. 
 98.  Woillard JB, Rerolle JP, Picard N, et al. Risk of diarrhoea in a long-term cohort of 
renal transplant patients given mycophenolate mofetil: the significant role of the 
UGT1A8 2 variant allele. Br J Clin Pharmacol. 2010;69:675-683. 
 99.  Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. 
Immunopharmacology. 2000;47:85-118. 
 100.  Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP 
dehydrogenases. J Biol Chem. 1993;268:27286-27290. 
 101.  Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate 
dehydrogenase type I and type II isoforms in human lymphocytes. Biochem 
Pharmacol. 2004;67:767-776. 
 102.  Natsumeda Y, Ohno S, Kawasaki H, et al. Two distinct cDNAs for human IMP 
dehydrogenase. J Biol Chem. 1990;265:5292-5295. 
 103.  Bremer S, Mandla R, Vethe NT, et al. Expression of IMPDH1 and IMPDH2 After 
Transplantation and Initiation of Immunosuppression. Transplantation. 
2008;85:55-61. 
 104.  Bremer S, Vethe NT, Rootwelt H, et al. Expression of IMPDH1 is regulated in 
response to mycophenolate concentration. Int Immunopharmacol. 2009;9:173-180. 
 105.  Wang J, Yang JW, Zeevi A, et al. IMPDH1 Gene Polymorphisms and Association 
With Acute Rejection in Renal Transplant Patients. Clin Pharmacol Ther. 2007. 
 106.  Sombogaard F, van Schaik RH, Mathot RA, et al. Interpatient variability in 
IMPDH activity in MMF-treated renal transplant patients is correlated with 
IMPDH type II 3757T>C polymorphism. Pharmacogenet Genomics. 2009;19:626-
634. 
    
 107.  Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of four DNA 
polymorphisms with acute rejection after kidney transplantation. Transpl Int. 
2008;21:879-891. 
 108.  Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate 
dehydrogenase activity is associated with clinical outcome after renal 
transplantation. Am J Transplant. 2004;4:2045-2051. 
 109.  Paine MF, Widmer WW, Hart HL, et al. A furanocoumarin-free grapefruit juice 
establishes furanocoumarins as the mediators of the grapefruit juice-felodipine 
interaction. Am J Clin Nutr. 2006;83:1097-1105. 
 110.  Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical 
significance of drug interactions between azole antifungals and select 
immunosuppressants. Pharmacotherapy. 2006;26:1730-1744. 
 111.  Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles 
with coadministration of ketoconazole. Clin Pharmacol Ther. 1997;62:41-49. 
 112.  Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor 
PXR is activated by compounds that regulate CYP3A4 gene expression and cause 
drug interactions. J Clin Invest. 1998;102:1016-1023. 
 113.  Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic 
structure and identification and functional characterization of natural allelic 
variants. Pharmacogenetics. 2001;11:555-572. 
 114.  Hesselink DA, van Schaik RH, van dH, I, et al. Genetic polymorphisms of the 
CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin 
inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254. 
 115.  Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the 
CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in 
whites and South Asians. Transplantation. 2005;79:499-502. 
    
 116.  Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) 
polymorphisms on the pharmacokinetics of tacrolimus in renal transplant 
recipients. Transplantation. 2004;78:1182-1187. 
 117.  Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic 
polymorphism on tacrolimus doses and concentration-to-dose ratio in renal 
transplant recipients. Transplantation. 2003;76:1233-1235. 
 118.  Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid 
pharmacodynamics and pharmacokinetics provide a basis for rational monitoring 
strategies. Am J Transplant. 2003;3:534-542. 
 119.  Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-
pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. 
Clin Pharmacol Ther. 1998;64:672-683. 
 120.  Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug 
monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug 
Monit. 2001;23:305-315. 
 121.  Le MY, Buchler M, Thierry A, et al. Individualized Mycophenolate Mofetil Dosing 
Based on Drug Exposure Significantly Improves Patient Outcomes After Renal 
Transplantation. Am J Transplant. 2007. 
 122.  van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil 
regimens for de novo renal transplant recipients: the fixed-dose concentration-
controlled trial. Transplantation. 2008;86:1043-1051. 
 123.  Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of 
steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney 
transplant recipients. Am J Transplant. 2008;8:307-316. 
 124.  Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, 
placebo-controlled multicenter trial comparing early (7 day) corticosteroid 
cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 
2008;248:564-577. 
    
 125.  Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant 
patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a 
meta-analysis of randomized, controlled trials. Transplantation. 2004;78:1548-
1556. 
 126.  Pascual J, Quereda C, Zamora J, et al. Updated metaanalysis of steroid withdrawal 
in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. 
Transplant Proc. 2005;37:3746-3748. 
 127.  Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation 
increases the risk of acute rejection but decreases cardiovascular risk. A meta-
analysis. Transplantation. 2010;89:1-14. 
 128.  Knight SR, Morris PJ. Steroid sparing protocols following nonrenal transplants; the 
evidence is not there. A systematic review and meta-analysis. Transpl Int. 
2011;24:1198-1207. 
 129.  Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow((R)) as a diagnostic tool 
for predicting infection and acute rejection in adult liver transplant recipients: 
Systematic review and meta-analysis. Liver Transpl. 2012. 
 130.  Food US, Administration D. Guidance for Industry: Bioanalytical Method 
Validation. 2001. 
 131.  Vethe NT, Bergan S. Determination of inosine monophosphate dehydrogenase 
activity in human CD4+ cells isolated from whole blood during mycophenolic acid 
therapy. Ther Drug Monit. 2006;28:608-613. 
 132.  Vethe NT, Gjerdalen LC, Bergan S. Determination of cyclosporine, tacrolimus, 
sirolimus and everolimus by liquid chromatography coupled to electrospray 
ionization and tandem mass spectrometry: assessment of matrix effects and assay 
performance. Scand J Clin Lab Invest. 2010;70:583-591. 
 133.  Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003;49:1041-
1044. 
    	
 134.  Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid 
chromatography-electrospray-tandem mass spectrometry. Clin Biochem. 
2005;38:328-334. 
 135.  King R, Bonfiglio R, Fernandez-Metzler C, et al. Mechanistic investigation of 
ionization suppression in electrospray ionization. J Am Soc Mass Spectrom. 
2000;11:942-950. 
 136.  Bonfiglio R, King RC, Olah TV, et al. The effects of sample preparation methods 
on the variability of the electrospray ionization response for model drug 
compounds. Rapid Commun Mass Spectrom. 1999;13:1175-1185. 
 137.  Matuszewski BK, Constanzer ML, Chavez-Eng CM. Matrix effect in quantitative 
LC/MS/MS analyses of biological fluids: a method for determination of finasteride 
in human plasma at picogram per milliliter concentrations. Anal Chem. 
1998;70:882-889. 
 138.  Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment 
of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. 
Anal Chem. 2003;75:3019-3030. 
 139.  Sagcal-Gironella AC, Sherwin CM, Tirona RG, et al. Pharmacokinetics of 
Prednisolone at Steady State in Young Patients With Systemic Lupus 
Erythematosus on Prednisone Therapy: An Open-Label, Single-Dose Study. Clin 
Ther. 2011. 
 140.  Morton JM, Williamson S, Kear LM, et al. Therapeutic drug monitoring of 
prednisolone after lung transplantation. J Heart Lung Transplant. 2006;25:557-563. 
 141.  Rustad P, Felding P, Franzson L, et al. The Nordic Reference Interval Project 2000: 
recommended reference intervals for 25 common biochemical properties. Scand J 
Clin Lab Invest. 2004;64:271-284. 
 142.  Green OC, Winter RJ, Kawahara FS, et al. Plasma levels, half-life values, and 
correlation with physiologic assays for growth and immunity. J Pediatr. 
1978;93:299-303. 
    

 143.  Miura M, Inoue K, Kagaya H, et al. Inter-individual difference determinant of 
prednisolone pharmacokinetics for Japanese renal transplant recipients in the 
maintenance stage. Xenobiotica. 2009. 
 144.  Miura M, Satoh S, Inoue K, et al. Influence of CYP3A5, ABCB1 and NR1I2 
polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. 
Steroids. 2008. 
 145.  Lock JF, Malinowski M, Schwabauer E, et al. Initial liver graft function is a 
reliable predictor of tacrolimus trough levels during the first post-transplant week. 
Clin Transplant. 2011;25:436-443. 
 146.  Goto M, Masuda S, Kiuchi T, et al. CYP3A5*1-carrying graft liver reduces the 
concentration/oral dose ratio of tacrolimus in recipients of living-donor liver 
transplantation. Pharmacogenetics. 2004;14:471-478. 
 147.  Ji E, Choi L, Suh KS, et al. Combinational Effect of Intestinal and Hepatic 
CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Recipients of Living 
Donor Liver Transplantation. Transplantation. 2012. 
 148.  Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose 
using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721-726. 
 149.  Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein 
to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 
1997;27:201-214. 
 150.  Liu C, Shang YF, Zhang XF, et al. Co-administration of grapefruit juice increases 
bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur J 
Clin Pharmacol. 2009;65:881-885. 
 151.  Brunet M, Cirera I, Martorell J, et al. Sequential determination of pharmacokinetics 
and pharmacodynamics of mycophenolic acid in liver transplant patients treated 
with mycophenolate mofetil. Transplantation. 2006;81:541-546. 
    
 152.  Hao C, Anwei M, Bing C, et al. Monitoring mycophenolic acid pharmacokinetic 
parameters in liver transplant recipients: prediction of occurrence of leukopenia. 
Liver Transpl. 2008;14:1165-1173. 
 153.  Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic 
acid after mycophenolate mofetil administration in liver transplant patients treated 
with tacrolimus. J Clin Pharmacol. 2001;41:268-276. 
 154.  Pisupati J, Jain A, Burckart G, et al. Intraindividual and interindividual variations 
in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin 
Pharmacol. 2005;45:34-41. 
 155.  Nashan B, Saliba F, Durand F, et al. Pharmacokinetics, efficacy, and safety of 
mycophenolate mofetil in combination with standard-dose or reduced-dose 
tacrolimus in liver transplant recipients. Liver Transpl. 2009;15:136-147. 
 156.  Bauer AJ, Boeckxstaens GE. Mechanisms of postoperative ileus. 
Neurogastroenterol Motil. 2004;16 Suppl 2:54-60. 
 157.  Wallden J, Thorn SE, Lovqvist A, et al. The effect of anesthetic technique on early 
postoperative gastric emptying: comparison of propofol-remifentanil and opioid-
free sevoflurane anesthesia. J Anesth. 2006;20:261-267. 
 158.  Jain A, Venkataramanan R, Kwong T, et al. Pharmacokinetics of mycophenolic 
acid in liver transplant patients after intravenous and oral administration of 
mycophenolate mofetil. Liver Transpl. 2007;13:791-796. 
 159.  Benichou AS, Blanchet B, Conti F, et al. Variability in free mycophenolic acid 
exposure in adult liver transplant recipients during the early posttransplantation 
period. J Clin Pharmacol. 2010;50:1202-1210. 
 160.  Budde K, Glander P, Bauer S, et al. Pharmacodynamic monitoring of 
mycophenolate mofetil. Clin Chem Lab Med. 2000;38:1213-1216. 
 161.  Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of 
mycophenolic acid-induced immunosuppression in renal transplant recipients. 
Transplantation. 1996;62:666-672. 
    	
 162.  Sanquer S, Maison P, Tomkiewicz C, et al. Expression of Inosine Monophosphate 
Dehydrogenase Type I and Type II After Mycophenolate Mofetil Treatment: A 2-
year Follow-up in Kidney Transplantation. Clin Pharmacol Ther. 2007. 
 163.  Vethe NT, Mandla R, Line PD, et al. Inosine monophosphate dehydrogenase 
activity in renal allograft recipients during mycophenolate treatment. Scand J Clin 
Lab Invest. 2006;66:31-44. 
 164.  Vannozzi F, Filipponi F, Di PA, et al. An exploratory study on pharmacogenetics 
of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from 
liver-transplant recipients. Transplant Proc. 2004;36:2787-2790. 
 165.  Liptak P, Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal 
allografts. Nat Clin Pract Nephrol. 2006;2:398-404. 
 166.  Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate 
mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am 
J Transplant. 2009;9:1607-1619. 
 
I

II

III

